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 Abbrevations 
 
15d-PGJ2 15-deoxy- ∆
12,14-prostaglandin J2
  
AA Arachidonic  acid 
ACF Aberrant  crypt  foci 
AOM Azoxymethane 
AP-2 Activator  protein  -2 
APC  Adenomatous polyposis coli 
ATM  Ataxia-telangectasia mutated kinase 
ATP Adenosine  triphosphate 
  
cDNA  Complementary deoxyribonucleic acid 
COX Cyclooxygenase 
cPGES  Cytosolic prostaglandin E synthase 
cPLA Cytosolic  phospholipase  A 
cAMP  Cyclic adenosine monophosphate 
CRE  cAMP response element 
CRTH2 Chemoattractant  receptor–homologous molecule expressed on TH2 cells 
  
DEPC Diethyl  pyrocarbonate 
DMEM  Dulbecco’s modified Eagle medium 
dNTPs Deoxyribonucleotide  triphosphates 
DTT Dithiothreitol 
  
ECACC  European Animal Cell Culture Collection 
EGFR  Epidermal growth factor receptor 
Egr-1  Early growth response 
EIA Enzyme  immunoassay 
ER Endoplasmic  reticulum 
ERK1/2  Extracellular signal-regulated kinase1/2 
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 FBS  Foetal Bovine serum 
FLAP 5-lipoxygenase-activating protein 
Fura-2/AM  Fura-2 acetoxymethyl ester 
  
GAPDH Glyceraldehyde  3-phosphate dehydrogenase 
GSH Glutathione 
  
H-Ras  Homologous to the oncogene of the Harvey rat sarcoma virus 
HSA  Human serum albumin 
HSF-1  Heat shock transcription factor 1 
HSP Heat  shock  protein 
  
IMN Indomethacin 
IP3 Inositol  (1,4,5)-trisphosphate 
iPLA  Intracellular phospholipase A  
  
JAK  Janus protein kinase 
JNK  c-jun N-terminal kinase 
  
LDH Lactate  dehydrogenase 
LT Leukotriene 
  
MAPEG  Membrane Associated Proteins in Eicosanoid and Glutathione metabolism
MAPK  Mitogen-activated protein kinases 
MGST1-L1 Membrane-bound  glutathione S-transferase 1-like-1 
Min  Multiple intestinal neoplasms 
mPGES Microsomal  prostaglandin E synthase 
mRNA  Messenger ribonucleic acid 
  
NAC  N-acetylcysteine 
NF-IL-6  Nuclear factor for interleukin-6 
NF-κB  Nuclear factor-kappa B 
NSAID Non-steroidal  anti-inflammatory drugs 
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PBS  Posphate buffered saline 
PG Prostaglandin 
PGT Prostaglandin  transporter 
PK Protein  kinase 
PPAR Peroxisome  proliferator-activated  receptor 
PPRE PPAR-response  element 
  
ROS  Reactive oxygen species 
RT-PCR  Reverse transcription-polymerase chain reaction 
RXR  Retinoid X receptor 
  
SAPK  Stress-activated protein kinases 
SDS-PAGE Sodium  dodecylsulfate  polyacrylamide gel electrophoresis 
Sp1  Specificity protein 1 
sPLA Secretory  phospholipase  A 
  
TBS-T  Tween Tris Base Saline 
Tx Thromboxane 
  
VEGF Vascular  endothelial growth factor 
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1 Introduction 
 
 
1.1 Prostaglandins 
 
Prostaglandins, thromboxanes and leukotrienes, collectively referred to as 
‘eicosanoids’, are the cyclooxygenase (COX) and lipooxygenase metabolites of arachidonic 
acid (AA) (Fig. 1.). Discovery of eicosanoids (from Greek eicosa=twenty; for twenty carbon 
fatty acid derivatives), was initiated in 1930. (Burr G. et al., 1930; Kurzrok R. et al., 1930; 
Euler U. 1934). First, it was found that exclusion of fat from the diet of rats led to growth 
retardation, reproductive disturbances, scaly skin, kidney lesions and excessive water 
consumption, which led to the discovery of essential fatty acids. Second, a factor with fatty 
acid properties and vasodepressor and smooth muscle-stimulating activity was identified that 
was termed "prostaglandin." Bergström and Samuelsson linked these observations when they 
elucidated the structures of the "classical" prostaglandins and demonstrated that they were 
produced from an essential fatty acid, AA (Bergström S. et al., 1964). 
All prostaglandins exhibit roughly the same structure as all are oxygenated fatty acids 
composed of 20 carbon atoms and contain a cyclopentane ring, a C-13 > C-14 trans-double 
bond, and a hydroxyl group at C-15 (Fig. 5, chapter 1.3). They were classified into types A to 
I, dependent on the modifications of this cyclopentane ring. The abbreviations are commonly 
followed by an index (for instance PGE2), which indicates the number of double bonds 
present in the various side chains attached to the cyclopentane ring. Based on the number of 
these double bonds, prostaglandins were classified into three series 1, 2, and 3. 
Prostaglandins are formed by most cells of the body and act as autocrine and paracrine 
lipid mediators, signalling at or immediately adjacent to their site of synthesis. They are not 
only key mediators of inflammation and involved in apoptosis, cell differentiation and 
oncogenesis, but also play critical physiologic roles in tissue homeostasis and function. For 
example, gastric mucosal protective function, sleep induction and vascular smooth muscles 
contraction and relaxation are all dependent upon these compounds. (Wallance J. 1992; Funk 
C. 2001; Muller R. 2004). The actions of prostaglandins are summarized in Fig. 1. 
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Fig. 1. Prostaglandin actions and synthesis. Mechanical trauma, cytokines, growth 
factors, or various inflammatory stimuli activate cells, triggering signalling, including 
cytosolic phospholipase (cPLA2) translocation to endoplasmatic reticulum and nuclear 
membranes, release of arachidonic acid from membrane lipids and production of PGH2 
intermediate by COX-2 or COX-1. Heterogeneous family of PGH2 metabolizing enzymes can 
form PGE2, PGD2, PGF2α, PGI2 (prostacyclin) and TxA2 (thromboxane). These 
prostaglandins may pass cell through a known prostaglandin transporter (PGT) to exert their 
actions on a family of prostaglandin receptors named EP1, EP2, EP3, EP4, DP1, DP2, FP, 
IP, TPα and TPβ. (Funk C., 2001) 
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1.1.1 Biological functions of prostaglandin E2
Prostaglandin E2 (PGE2) is a major cyclooxygenase product in a number of 
physiological settings. It was first isolated and its structure determined in the 1960-s. 
(Samuelsson B. 1963). Thereafter, this prostaglandin was found in many different tissues. 
PGE2 plays a protective role in maintaining the integrity of the gastric mucosa (Woo S. et al. 
1986). The PGE2 production in the kidney is critical for normal renal function by preserving 
renal blood flow and glomerular filtration rate in settings of physiological stress, modulating 
salt and water transport in the distal tubule, and stimulating renin release from the 
juxtaglomerular apparatus (Breyer M. et al. 2001). PGE2 was also shown to play a role in the 
maintenance of blood pressure, particularly in the setting of salt overload (Kennedy C. et al. 
1999). In certain instances, PGE2 was observed to have multiple and apparently opposing 
functional effects. For example, PGE2 elicits both smooth muscle relaxation and constriction 
(Walch L. et al. 2001; Davis R. et al. 2004). Complexity was also observed in modulation of 
the immune response by PGE2; it was shown that PGE2 regulates the function of many cell 
types including macrophages, dendritic cells, T and B lymphocytes leading to both pro- and 
anti-inflammatory effects. (Hata A. et al. 2004). PGE2 is also associated with oncogenesis. 
PGE2 signalling promotes tumour angiogenesis (Kurie J. et al. 2001), increases cell 
proliferation and stimulates oncogenesis (Pai R. et al. 2002). 
The diverse effects of PGE2 may be accounted for in part by the existence of four G-
protein-coupled receptors, EP1, EP2, EP3, and EP4, and heterogeneity in the coupling of 
these receptors to intracellular signal transduction pathways (Fig. 2). Synthesized PGE2 is 
released mainly through a prostaglandin transporter (PGT) (Schuster V. 1998) out of the cells 
and then binds to receptors in the vicinity of the site of PGE2 production. Of the four known 
EP receptors, EP3 and EP4 receptors bind PGE2 with the highest affinity (Kd ~ 1 nM), 
whereas EP1 and EP2 receptors bind with lower affinity (Kd > 10 nM) (Abramovitz 2000). 
The EP1 receptor mediates PGE2-induced elevation of free Ca
2+ concentration, whereas the 
EP2 and EP4 receptors are coupled to Gs-type G protein and their activation leads to an 
increase in cyclic AMP (cAMP) levels. The signalling pathway of the EP3 receptor mediates 
inhibition of adenylate cyclase via Gi (Narumiya S. et al. 1999). 
Among the prostanoid receptors EP3 and EP4 receptors are widely distributed 
throughout the body. In contrast, the distribution of EP1 is restricted to several organs, such as 
the kidney, lung, and stomach, and EP2 is the least abundant among the EP receptors. 
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However, EP2 is effectively induced in the response to inflammatory stimuli (Narumiya S. et 
al. 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Signal transduction of prostaglandin E2 receptors. PGE2 is actively transported out 
of the cell, where it exerts the effect by coupling to its heptahelical transmembrane receptors, 
EP1, EP2, EP3 and EP4 to activate second messengers, such as cAMP and inositol (1,4,5)-
trisphosphate (IP3), and intracellular signalling cascades (Jabbour H. et al. 2001). 
 
 
1.1.2 Prostaglandin E2 and cancer 
During the last years COX-2, a subset of prostanoids and prostanoids receptors was 
clearly established as crucial players in oncogenesis that regulate, and are regulated by, 
pathways with essential functions in oncogenesis (Muller R. 2004). The use of non-steroidal 
anti-inflammatory drugs (NSAID), which inhibit COX enzymes, was linked to reduced cancer 
risk in multiple tissues including those of the breast, colon, prostate, and lung (Zha S. et al. 
2004). Among the various downstream prostaglandins, PGE2 has long been suggested as the 
key player. Stimulatory effect of prostaglandin E was first observed in dog kidney cells. 
These cells required PGE2 or PGE1 for growth in serum-free media (Taub M. et al. 1979, 
Taub M. et al. 1983). Furthermore, increased amount of PGE2 was found in breast and colon 
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cancer (Karmali R. et al. 1983, Yoshimatsu K. et al. 2001) and inducible microsomal 
prostaglandin E synthase-1 was described to be constitutively expressed in several cancers, 
most of which also express COX-2 constitutively. (Yoshimatsu K. et al. 2001, Jabbour H. et 
al. 2001, Yoshimatsu K., Golijanin D. et al. 2001). 
Several reports have demonstrated increased PGE2 levels in neoplastic colorectal 
lesions compared with normal mucosa (Rigas B. et al. 1993, Pugh S. et al. 1994;Yoshimatsu 
K. et al. 2001). There is a body of evidence, beyond the association between a cancer 
phenotype
  and increased levels of PGE2, suggested that PGE2 also contributes to the 
development and progression of colorectal cancer. The PGE2 level increases in a size-
dependent manner in colorectal adenomas in familial adenomatous polyposis patients (Hull 
M. et al. 2004). PGE2 can induce angiogenesis in vitro and increases cellular resistance to 
apoptosis (Ben-Av P. et al. 1995), enhancing the survival and motility (Sheng H. et al. 1998, 
Sheng H. et al. 2001) in colon cancer. Immune surveillance is also inhibited by PGE2 (Balch 
C. et al. 1984). Cumulative evidence indicated that COX-2-derived PGE2 provides growth 
advantage to colorectal carcinomas through transactivation of the epidermal growth factor 
receptor (EGFR) signalling system (Sheng H. et al. 2001; Pai R. et al. 2002). On the other 
hand, PGE2 exposure
 induces the expression of VEGF (vascular endothelial growth factor) in 
colon cancer cells (Fukuda R. et al. 2003). 
In addition to these findings, studies with experimental
 animals suggested that PGE2 
promotes tumorigenesis. Treatment with anti-PGE2 monoclonal antibody retards the growth
 of 
a transplantable lung tumour (Stolina M. et al. 2000). Knockout mouse studies shown that 
only the prostaglandin E receptors, but not any other single prostaglandin receptor knockout 
mice, show a significant decrease in the number of aberrant crypt foci when compared with 
the wild type controls (Zha S. et al. 2004). Three of four identified G-protein coupled PGE2 
receptors are involved in enhancement of colon carcinogenesis in different mouse models of 
oncogenesis. Disruption of both EP2 alleles was reported to inhibit tumour cell proliferation, 
tumour growth, and led to reduced polyp incidence and size in Apc
∆716 mice, employed as a 
model of familial adenomatous polyposis (Seno et al. 2002; Sonoshita et al. 2001). These 
tumours show decreased microvessel density indicating a critical role for EP2 in tumour 
angiogenesis (Seno et al. 2002). The role of EP4 was studied in another mouse model of 
intestinal oncogenesis, i.e., the formation of polyps in mice treated with the chemical 
carcinogen, azoxymethane (AOM) (Mutoh et al. 2002). Genetic inactivation of EP4 led to a 
44% reduction in the numbers of polyps. Antagonists of EP1 and EP4, similarly suppressed 
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aberrant crypt foci (ACF) formation in this mouse model. An EP1-selective antagonist 
reduced the colon cancer incidence, multiplicity and volume, along with cell proliferation in 
colon tumour cells (Niho N. et al. 2005). In contrast, expression of EP3 mRNA is markedly 
decreased in colon cancer tissues, compared with normal colon mucosa. Deficiency of EP3 
receptor had no effect on the early stages of cancer in AOM treated mice; however, long term 
in vivo examination of AOM induced colon tumour development demonstrated enhancement 
of tumour incidence and multiplicity. Moreover, the size of the tumours was significantly 
increased. Thus, suggesting that the EP3 receptor does not influence the early stage of colon 
carcinogenesis, including ACF formation, but could play an important role in cancer 
development at a later stage (Shoji Y. et al. 2004). Some studies have also shown that EP3 
and EP2 receptors have been implicated in tumor-associated angiogenesis via VEGF 
production (Hull M. et al. 2004). 
 
 
1.2 Cyclopentenone prostaglandins 
 
The cyclopentenone prostaglandins PGA2, PGA1, and PGJ2 are formed by dehydration 
within the cyclopentane ring of PGE2, PGE1, and PGD2, respectively. PGJ2 is metabolized 
further to yield ∆
12-PGJ2 and 15-deoxy- ∆
12,14-PGJ2 (15d-PGJ2). Cyclopentenone 
prostaglandins contain a cyclopentenone ring structure, which is characterized by the presence 
of a chemically reactive α,β-unsaturated carbonyl. The α,β-unsaturated carbonyl group 
contains an electrophilic centre which makes these prostaglandins susceptible to undergo 
addition reactions with nucleophiles such as the free sulfhydryl group of cysteine residues 
located in reduced glutathione or cellular proteins (Fig. 3) (Honn K. et al. 1985, Atsmon J. et 
al. 1990, Parker J. et al. 1992). Alkylation of the exposed cysteine residues on key cellular 
target proteins results in changes of function of the targets, thus explaining the bioactivity of 
cyclopentenone prostaglandins (Straus D. et al. 2001). 
Although prostaglandins in general was shown to stimulate cell proliferation, the 
cyclopentenone prostaglandins were reported to induce apoptosis in various malignant and 
transformed cells (Kim I. et al. 1993; Joubert A. et al. 2003; Chen Y. et al. 2003; Straus D. et 
al. 2001). In addition to
  their proapoptotic properties, various compounds within the 
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cyclopentenone prostaglandin family possess potent anti-inflammatory and anti-viral activity. 
Most actions of the cyclopentenone prostaglandins do not appear to be mediated by binding to 
G-protein coupled prostanoid receptors (Straus D. et al. 2001). 
 
 
 
Fig. 3. Covalent binding of cyclopentenone ring to signalling molecules. The specific 
effect of cyclopentenone prostaglandins are mediated through their covalent binding to 
intracellular proteins. This is due to their reactive cyclopentenone ring (Powell W. 2003). 
 
 
1.2.1 15-deoxy- 
∆12,14-PGJ2
15d-PGJ2 was initially identified as a product of albumin-catalyzed transformation of 
PGD2 in vitro (Fitzpatrick F. et al. 1983). Later on, it was discovered that PGD2 is converted 
to PGJ2, a direct precursor of ∆
12-PGJ2 and 15d-PGJ2. Serum albumin is involved only in the 
process leading from PGJ2 to ∆
12-PGJ2 (Fig. 4) (Shibata T. et al. 2002). Considerable interest 
was generated in 1995 with the discovery that 15d-PGJ2 is an activating ligand for 
peroxisome proliferator-activated receptor-γ (PPARγ) (Forman B. et al. 1995, Kliewer S. et 
al. 1995). 
15d-PGJ2 may alter cellular functions by multiple mechanisms. This cyclopentenone 
was shown to inhibit the expression of a variety of proinflammatory genes, including COX-2 
(Straus D. et al. 2000; Subbaramaiah K. et al. 2001; Sanchez-Gomez F. et al. 2004; Straus D. 
et al. 2001). 15d-PGJ2 was identified in inflammatory fluids and it was demonstrated that 
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levels of this compound increase during the resolution phase of inflammation (Gilroy D. et al. 
1999). Together with the known potent anti-inflammatory activity of 15d-PGJ2, these results 
suggest that 15d-PGJ2 may play a role as a naturally occurring feedback inhibitor of 
inflammation in vivo. 
 
 
 
Fig. 4. Generation of 15d-PGJ2. PGD2 metabolism. PGD2 is sequentially converted 
to PGJ2 and 15d-PGJ2 in an albumin-independent manner and human serum albumin (HSA) 
is involved only in the process leading from PGJ2 to ∆
12-PGJ2. 
 
 
Some of the effects of 15d-PGJ2 are mediated by its ability to bind and activate 
PPARγ (Straus D. et al. 2001; Inoue H. et al. 2000; Shimada T. et al. 2002) However, 15d-
PGJ2 can induce a variety of responses independently of PPARγ because of the reactive 
cyclopentenone ring of this prostaglandin (Nosjean O. et al. 2002). 15d-PGJ2 regulates the 
activity of several signalling molecules and transcription factors including nuclear factor-
kappa B (NF-κB), c-Jun, H-Ras (homologous to the oncogene of the Harvey rat sarcoma 
virus) and heat shock protein (HSP)70 (Straus D. et al. 2000, Rossi A. et al. 2000; Perez-Sala 
D. et al. 2003; Powell W. 2003; Cippitelli M. et al. 2003). In addition to the intracellular 
effects of 15d-PGJ2 on transcription factors and signalling molecules, 15d-PGJ2 can also act 
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on cell membrane receptors, DP1 and chemoattractant receptor–homologous molecule 
expressed on TH2 cells (CRTH2) (Monneret G. et al. 2002; Wright D. et al. 1998). 
There is a body of evidence indicating that 15d-PGJ2 possesses anti-neoplastic 
properties because of its inhibitory effects on tumour cell proliferation and angiogenesis. 
(Nencioni A. et al. 2003; Michalik L. et al. 2004; Straus D. et al. 2001). This cyclopentenone 
was shown to be the most active anti-tumour compound in the PGJ2 series (Kato T. et al. 
1986). Low levels of 15d-PGJ2 were observed in metastatic tissues compared to non-
metastatic tissues, suggesting that 15d-PGJ2 may influence the development of cancer and its 
progression to metastasis in vivo (Badawi A. et al. 2002). However, the precise mechanisms 
underlying the ability of 15d-PGJ2 to act as an anti-tumoral agent are yet poorly understood. 
 
 
1.3 Enzymes involved in prostaglandin biosynthesis 
 
1.3.1 Phospholipase A2 enzymes 
Arachidonic acid, the common precursor of eicosanoids, is stored at the sn-2 position 
of membrane glycerophospholipids, and released by the hydrolytic action of phospholipase 
A2 (PLA2) enzymes (Fig. 1). Several PLA2s were identified based on their nucleotide gene 
sequences. They were classified mainly into three groups: (i) cytosolic PLA2 (cPLA2), (ii) 
Ca
2+-dependent secretory PLA2 (sPLA2), and (iii) Ca
2 +-independent intracellular PLA2 
(iPLA2). Under stimulated conditions, Ca
2+-dependent cytosolic PLA2s (cPLA2s) and several 
secretory PLA2s (sPLA2s) are responsible for releasing AA from glycerol-based 
phospholipids to form PGs and related molecules (Jones R. et al. 2003). Mitogen-activated 
protein kinases (MAPK), protein kinase A (PKA) and C (PKC) were shown to regulate PLA2 
activity (Chakraborti S. 2003; Pinelli E. et al. 1999; Antonio V. et al. 2002; Thomas G. et al. 
2000). The upregulation of PLA2 enzymes results in the production of a free pool of AA that 
is required for the synthesis of various eicosanoids. 
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Fig. 5. Biosynthetic pathways of prostanoids. Arachidonic acid is converted to the 
prostanoid precursor PGG2, which is subsequently peroxidized to PGH2. Both enzymatic 
reactions are catalyzed by the COX protein, which consists of two forms: the endoplasmic 
reticulum-localized COX-1, and COX-2, that acts predominantly at the nuclear envelope. 
Prostaglandin H2 spontaneously rearranges or is enzymatically isomerised, oxidized, or 
reduced to yield bioactive prostaglandin isomers, some of which are shown. 
 
 
1.3.2 Cyclooxygenase enzymes 
AA is metabolized to the unstable intermediate prostanoid, PGH2, by the action of 
COX enzymes. COX, also known as prostaglandin H synthase, is a heme-containing enzyme 
that catalyzes two sequential enzymatic reactions; first, the bis-oxygenation of AA leading to 
the production of PGG2 (COX reaction) and second, reduction of 15-hydroperoxide of PGG2 
leading to the formation of PGH2 (hydroperoxidase reaction) via separate active sites of the 
enzyme (Smith W. et al. 2000). Two COX isoforms, COX-1 and COX-2, were found in 
mammals. Both enzymes are encoded by separate genes on different chromosomes: COX-1 is 
located on chromosome 9, COX-2 on chromosome 1. COX-1 and COX-2 display ~ 60% 
sequence identity and both possess homodimeric structure. Both COX have a molecular 
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weight of 72 kDa made up of a dimeric complex of two polypeptides, each of which requires 
one molecule of heme for maximal catalytic activity (Roth G. et al. 1981; Brown J. et al. 
2005). 
It is commonly considered that COX-1 is constitutively expressed in a wide variety of 
cells and plays a housekeeping role, whereas COX-2 is a stimulus-inducible enzyme that is 
implicated in pathological conditions, such as inflammation, pain, fever and cancer (Morita I. 
2002). In general, COX-1 is more enriched in the Golgi, endoplasmic reticulum (ER) than in 
the perinuclear envelope and COX-2 is located predominantly in the perinuclear envelope. 
The promoter structure of the COX-1 gene suggests that specificity protein 1 (Sp1), activator 
protein -2 (AP-2), and nuclear factor for interleukin-6 (NF-IL-6) are involved in the 
regulation of COX-1 gene expression. The two Sp1 sites contribute to constitutive expression 
of COX-1 (Xu X. et al. 1997). The promoter region of the COX-2 gene reveals a typical 
feature of the immediate early genes, which contains various transcription elements, such as 
NF-IL-6, AP-2, Sp1, NF-kB and cAMP response element (CRE). Three mitogen-activated 
protein kinase (MAPK) cascades: (i) extracellular signal-regulated kinase1/2 (ERK1/2), (ii) c-
jun N-terminal kinase/stress-activated protein kinases (JNK/SAPK), (iii) p38 (Su B. et al. 
1996; Simmons D. et al. 2004; Murakami M. et al. 2004) contribute to the induction of COX-
2 gene concertedly or independently. The nuclear receptor, peroxisome proliferator-activated 
receptor (PPAR) γ was also shown to regulate the expression of COX-2 (Inoue H. et al. 2000; 
Straus D. et al. 2000; Meade E. et al. 1999). 
COX-2 induction is associated with various premalignant and malignant lesions of 
epithelial and nonepithelial origin. Gastric, hepatic, esophageal, pancreatic, head and neck, 
lung, breast, bladder, cervical, endometrial, skin, and colorectal cancers all shown to display 
elevated COX-2 expression when compared with nonmalignant tissue (Koki A. et al. 2002). 
In regard to experimental evidence, nonselective inhibitor of COX-2, NSAIDs, have been 
known to inhibit cancer formation in rodent models of colorectal cancer since the 1980s, and 
the development of selective COX-2 inhibitors has shown equal promise in rodent models and 
in several models of colorectal cancer (Brown J. et al. 2005). More compelling evidence for 
the role of COX-2 in the cancer formation was provided by genetic studies in mice. Genetic 
inhibition of COX-2 reduced the development of colonic polyps in the adenomatous polyposis 
coli
∆716 (APC
∆716) murine model (Oshima M. et al. 1996). In a model of mammary 
tumorigenesis, overexpression of COX-2 alone in mammary glands was sufficient to induce 
cellular transformation and resulted in the formation of breast carcinomas (Liu C. et al. 2001). 
Similarly, COX-2 overexpression in basal keratinocytes induced hyperplasia, skin 
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premalignancy and skin malignancy (Neufang G. et al. 2001; Muller-Decker K. et al. 2002). 
Together these studies underline the important role of COX-2 in the initiation and promotion 
of carcinogenesis. 
In 2002, Chandrasekharan and colleagues reported the isolation of a splice-variant of 
COX-1 mRNA found in highest concentrations in the cerebral cortex and heart of the dog, 
which they termed ‘‘COX-3’’. COX-3 is made from the COX-1 gene but retains intron 1. 
This intron contains an open reading frame that introduces an insertion of 30–34 amino acids, 
depending on mammalian species. COX-3 was postulated to be a 65-kDa protein. COX-3 
mRNA is mainly expressed in cerebral cortex and heart and exhibits glycosylation-dependent 
COX activity. Comparison of COX-3 with COX-1 and COX-2 demonstrates that this enzyme 
is selectively inhibited by analgesis/antipyretic drugs, such as acetaminophen and phenacetin 
(Murakami M. et al. 2004). 
 
 
1.4 Prostaglandin E synthases 
 
The final step of the PGE2-synthesizing cascade is a nonoxidative rearrangement of 
the COX product, PGH2, into PGE2 (Fig. 5). Although this isomerization may also occur 
nonenzymatically, living cells produce PGE2 via a catalytic reaction, which is attributed to 
several discovered proteins: cytosolic prostaglandin E synthase, microsomal prostaglandin E 
synthase-1 and microsomal prostaglandin E synthase -2 (Tanioka et al. 2000; Jakobsson PJ. et 
al. 2000; Watanabe et al. 1999). 
 
1.4.1 Cytosolic prostaglandin E synthase 
Cytosolic prostaglandin E synthase (cPGES) is a 23 kDa cytosolic protein that is 
identical to the Hsp90-associated protein p23 (Tanioka T. et al. 2000). The gene for cPGES is 
localized to human chromosome 12q13.13. cPGES is expressed ubiquitously and 
constitutively in the cytosol of a variety of tissues and cells, with an exception in rat brain in 
which LPS treatment increases its amount several-fold (Tanioka T. et al. 2000). cPGES 
resides predominantly in the cytosol and moves to the endoplasmic reticulum after Ca
2+ 
ionophore challenge. Cotransfection and antisense experiments indicated that cPGES is 
capable of converting COX-1-, but not COX-2- derived PGH2 to PGE2 in cells. Thus, in line 
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with the roles of COX-1 in vivo, cPGES may contribute physiologically to the production of 
PGE2 required for the maintenance of tissue homeostasis. cPGES activation in cells requires 
its binding to Hsp90 (Tanioka T. et al. 2003) and phosphorylation by casein kinase 2 
(Kobayashi T. et al. 2004). 
cPGES requires glutathione (GSH) as an essential cofactor for its activity. The Km and 
Vmax values of recombinant cPGES for PGH2 are estimated to be 14 µM and 0.19 µM/min/mg 
protein, respectively (Tanioka T. et al. 2000). 
 
1.4.2 Microsomal prostaglandin E synthase-1 
Membrane associated prostaglandin E synthase-1 (mPGES-1), originally designated 
MGST1-L1 (membrane-bound glutathione S-transferase 1-like-1) belongs to the Membrane 
Associated Proteins in Eicosanoid and Glutathione metabolism (MAPEG) family (Jakobsson 
PJ. et al. 1999). This protein family consists of six human proteins including 5-lipoxygenase-
activating protein (FLAP), leukotriene C4 (LTC4) synthase, microsomal glutathione S-
transferase 1 (MGST1), MGST2, MGST3, and MGST1-L1 (Jakobsson PJ. et al. 2000). All 
MAPEG proteins show significant homology and have similar molecular masses of 14–18 
kDa. 
mPGES-1 requires GSH as an essential cofactor for its activity. The Vmax value of 
purified His6-mPGES-1 was 170 µM/min/mg for the conversion of PGH2 to PGE2 at 37°C 
and Km for PGH2 was 160 µM. Two-dimensional crystal analysis revealed that mPGES-1 
protein forms a trimer (Thoren S. et al. 2003). 
The gene for human mPGES-1 maps to chromosome 9q34.3 (Forsberg L. et al., 2000). 
The promoter of the human mPGES-1 gene contains binding sites for AP-1 and early growth 
response (Egr-1) transcriptional factor. p38 and p42/44 MAPK, ERK as well as JNK are all 
involved in the regulation of mPGES-1 in human (Han R. et al. 2002; Giannico G. et al. 
2005). 
mPGES-1 is involved in various physiological and pathological events, such as 
inflammation, reproduction, bone metabolism, Alzheimer’s disease and tumorigenesis 
(Murakami M. et al. 2004). Stimulation of different cultured cells with proinflammatory 
stimuli leads to a marked elevation of mPGES-1 expression with a concomitant elevation of 
COX-2 expression and PGE2 production. There are some data indicating an important role for 
the transcription factors NF-κB and PPARγ in the co-ordinate regulation of the COX-
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2/mPGES pathway (Catley M. et al. 2003; Mendez M. et al. 2003). However, the kinetic 
induction of COX-2 and mPGES-1 often differs significantly (Stichtenoth D. et al. 2001), 
suggesting distinct regulatory mechanisms for their expression. COX-2 and mPGES-1 are 
colocalized in the perinuclear membrane. Colocalization of the two sequential biosynthetic 
enzymes in the same subcellular compartment may allow efficient transfer of the unstable 
substrate PGH2 from COX-2 to mPGES-1 (Murakami M. et al. 2002; Murakami M. et al. 
2000; Mancini J. et al. 2001). 
Involvement of mPGES-1 downstream of COX-2 in tumorigenesis has been suggested 
by the observation that transfection of mPGES-1 in combination with COX-2, but not with 
COX-1, into HEK293 cells leads to cellular transformation, which was manifested by 
aggressive growth, piling up and aberrant morphology (Murakami M. et al. 2000). The COX-
2/mPGES-1-cotransfected cells formed a number of large colonies in soft agar culture and 
were tumorigenic when implanted into nude mice (Kamei D. et al. 2003). Furthermore, the 
expression of mPGES-1 as well as COX-2 is markedly elevated in several types of cancer, 
including human colon adenomas and cancers and overexpressing Ras, a well established 
signalling molecule in cancer, caused a several-fold increase in mPGES promoter activity 
(Yoshimatsu K. et al. 2001, Yoshimatsu K., Golijanin D. et al. 2001). 
 
1.4.3 Microsomal prostaglandin E synthase -2 
Membrane-associated, GSH-non specific, PGES-2 was originally purified from 
microsomal fraction of bovine heart (Watanabe K. et al. 1999), was cloned and termed 
mPGES-2. The gene for mPGES-2 is localized to human chromosome 9q33-34 in proximity 
to the genes for mPGES-1 and COX-1 (Tanikawa N. et al. 2002). 
The cDNA encodes a 41 kDa protein that contains an N-terminal hydrophobic region, 
which is removed by proteolytic processing in the Golgi membrane. Proteolytic cleavage 
occurs presumably between amino acid residues 87-88 and then truncated protein is 
distributed in the cytosol with a trend to be enriched in the perinuclear region. Both, intact and 
the N-terminal truncated, mPGES-2 show similar catalytic activities (Tanikawa N. et al. 
2002). 
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Most recently, N-terminal truncated mPGES-2 complexed with the non-steroidal anti-
inflammatory drug indomethacin (IMN) has been crystallized and the complex structure has 
been determined (Fig. 6). 
 
 
 
Fig. 6. Overall structure of mPGES-2. A dimeric mPGES-2 sits on the lipid bilayer. Two 
subunits are shown by aquamarine and light-pink, respectively. Parts of the truncated N-
terminal section (residues 1–87) and disorder section (residues 88-99) shown by white are 
built based on a secondary structure prediction and a hydropathic index analysis, and are 
apparently associated with the lipid bilayer (Yamada T. et al. 2005). 
 
 
mPGES-2 forms a dimer being attached to the lipid membranes by anchoring the N-
terminal section. Two hydrophobic pockets connected to form a V shape are located in the 
bottom of a large cavity. It was supposed, that when PGH2 binds to the cavity in mPGES-2 
and the endoperoxide moiety of PGH2 is located in the catalytic site, the isomerization 
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reaction is initiated by a proton transfer from cystein110 to O11 of PGH2. mPGES-2 catalyzes 
the isomerization of PGH2 to PGE2 without the presence of an R–SH compound (Yamada T. 
et al. 2005). The Vmax and Km values for PGH2 of the purified recombinant mPGES-2 were 
about 3.3 µmol/min/mg of protein and 28 µM, respectively (Tanikawa N. et al. 2002). 
mPGES-2 can be coupled with both COX-1 and COX-2 enzymes. mPGES-2 is 
expressed constitutively in several tissues in which mPGES-1 expression is relatively low and 
is not increased appreciably during tissue inflammation (Murakami M. et al. 2003, Guay J. et 
al. 2004). However, considerable elevation of mPGES-2 expression was observed in human 
colorectal cancer (Murakami M. et al. 2003). The regulation of mPGES-2 remains unclear. 
Nevertheless, there is evidence that neither MAPK kinases nor hormones are capable to 
regulate the expression of mPGES-2 (Giannico G. et al. 2005, Duffy D. et al. 2005). 
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2. Aim of the present investigation 
 
PGE2 is the major prostaglandin involved in colorectal carcinogenesis. PGE2 induces 
cell proliferation, inhibits apoptosis as well as promotes motility and angiogenesis, moreover 
elevated levels of PGE2 have been shown in colorectal cancer. The biosynthesis of PGE2 is 
accomplished by several terminal prostaglandin E synthases through catalytical conversion of 
the COX product PGH2. Among the known terminal prostaglandin E synthases, mPGES-1 
and mPGES-2 were found to be overexpressed in colorectal cancer, however the role and 
regulation of these enzymes in this tumour entity are yet not fully understood. 15d-PGJ2 is a 
cyclopentenone prostaglandin, which possesses anti-neoplastic, anti-inflammatory and anti-
viral activities. The inhibition of cell growth and induction of apoptosis by this compound 
was previously described. Moreover, 15d-PGJ2 was shown as a key regulator of negative 
feedback of the COX pathway in an inflammatory setting. Based on these data, it was planned 
to determine the potential implication of 15d-PGJ2 in PGE2 mediated colorectal cancer 
promotion. 
It was demonstrated that mPGES-1 and COX-2 enzymes are co-regulated, however, in 
several cases, mPGES-1 was not found to be linked to COX-2, and PGE2 production by 
mPGES-2 using PGH2 supplied by both COX-1 and COX-2, has also been demonstrated. In 
contrast, expression of cPGES has been postulated to be linked with COX-1. There is also a 
body of evidence, indicating a link between PG biosynthesis and 15d-PGJ2 by means of a 
feedback control of COX-2 by this PG metabolite. Moreover, 15d-PGJ2 has been shown to 
inhibit mPGES-1 in vitro. 
In the present study it was planned to investigate the effect of 15d-PGJ2 on PGES 
expression in colorectal cancer cell lines and to find out which COX isoforme is linked to this 
regulation. 
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3. Materials and Methods 
 
3.1 Materials 
 
3.1.1 Chemicals 
15-deoxy-∆
12,14-prostaglandin J2   Alexis, Carlsbad, CA, USA 
2-propanol 
Acetic acid  
 
Merck, Darmstadt, Germany 
Acrylamid solution  AppliChem, Darmstadt, Germany 
Agarose NEEO  Roth, Karlsruhe, Germany 
Ammonium peroxodisulfate  Merck, Darmstadt, Germany 
Arachidonic acid  Cayman Chemical, Ann Arbor, MI, USA 
ATP  Sigma-Aldrich, St. Louis, MO, USA 
BW245C Cayman  Chemical, Ann Arbor, MI, USA 
CaCl2
Chloroform 
Citric acid 
 
Merck, Darmstadt, Germany 
Complete
TM Roche Diagnostics GmBH, Manheim, 
Germany 
Coomassie protein assay, precision 
plus protein
TM standards 
 
Bio-Rad, Hercules, Ca, USA 
Crystal violet  AppliChem, Darmstadt, Germany 
Developer solution  Fujifilm, Tokyo, Japan 
Diethyl pyrocarbonate (DEPC) 
Dithiothreitol 
 
Sigma-Aldrich, St. Louis, MO, USA 
DNA gel loading buffer ( 6× )  Novagen, Madison, WI, USA 
dNTPs  Bioline, London, U.K. 
Dulbecco’s modified Eagle medium (DMEM) 
Dulbecco’s PBS (1×) 
 
Gibco/ Invitrogen, Karlsruhe, Germany 
Ethanol  Merck, Darmstadt, Germany 
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Ethidium bromide 
FeCl2 × 4H2O 
 
AppliChem, Darmstadt, Germany 
Fixer solution  Fujifilm, Tokyo, Japan 
Foetal Bovine serum (FBS)  Gibco/ Invitrogen, Karlsruhe, Germany 
Formaldehyde  Otto Fishar GmBH, Saarbrueken, 
Germany 
Forskolin 
Fura-2 acetoxymethyl ester 
 
Sigma-Aldrich, St. Louis, MO, USA 
Geneticin  Gibco/ Invitrogen, Karlsruhe, Germany 
Glucose  Sigma-Aldrich, St. Louis, MO, USA 
Glycin  Roth, Karlsruhe, Germany 
HCl  Merck, Darmstadt, Germany 
HEPES  Sigma-Aldrich, St. Louis, MO, USA 
 
Hyper film 
Amersham Biosciences, 
Buckinghamshire, U.K. 
KCl 
K2HPO4 
KH2PO4 
KOH 
 
 
Merck, Darmstadt, Germany 
Lactate dehydrogenase kit  Roche, Mannheim, Germany 
MCC-555  Cayman Chemical, Ann Arbor, MI, USA 
Methanol  Mallinckrodt Baker B. V., Deventer, 
Holland 
MgCl2 Merck, Darmstadt, Germany 
MuLV reverse transcriptase  Applied Biosystems, Branchburg, NJ, 
USA 
N-acetylcysteine  Sigma-Aldrich, St. Louis, MO, USA 
NaCl  Merck, Darmstadt, Germany 
Nitrocellulose transfer membrane  BioSciense, San Jose, Ca, USA 
Non-essential Amino Acid (100×)  Gibco/ Invitrogen, Karlsruhe, Germany 
Oligo d(T)16 Applied Biosystems, Branchburg, NJ, 
USA 
Oligonucleotides BioSpring,  Frankfurt,  Germany 
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Penicillin/Streptomycin 10000U  Gibco/ Invitrogen, Karlsruhe, Germany 
Pico Green (dsDNA Quantitation Kit)  MolecularProbes/Invitrogen, Karlsruhe, 
Germany 
Ponceau S stain 
Probenecid 
 
Sigma-Aldrich, St. Louis, MO, USA 
Prostaglandin A2
Prostaglandin E2 enzyme immunoassay kit 
Prostaglandin D2
 
Cayman Chemical, Ann Arbor, MI, USA 
Ready-Load
TM 100 bp DNA Ladder  Invitrogen, Carlsbad, Ca, USA 
RNase inhibitor  Applied Biosystems, Branchburg, NJ, 
USA 
RNAzol  ISO-TEX Diagnostics, Friendswood, TX, 
USA 
Roti Load 1  Roth, Karlsruhe, Germany 
SDS  AppliChem, Darmstadt, Germany 
Sodium Pyruvate 100 mM  Gibco/ Invitrogen, Karlsruhe, Germany 
Sucrose  AppliChem, Darmstadt, Germany 
SuperSignal
® West Pico Luminol/Enhancer 
Solution 
SuperSignal
® West Pico Stable Peroxide 
Solution 
 
 
Pierce, Rockford, IL, USA 
Taq polymerase  Applied Biosystems, Branchburg, NJ, 
USA 
TBE buffer (10 ×)  Invitrogen, Carlsbad, Ca, USA 
TEMED  AppliChem, Darmstadt, Germany 
TRIS  Sigma-Aldrich, St. Louis, MO, USA 
Trypan blue stain, 0,4% 
Trypsin-EDTA (10×) 
 
Gibco/ Invitrogen, Karlsruhe, Germany 
Tween-20  Sigma-Aldrich, St. Louis, MO, USA 
 
 
Prostaglandin H2 was a generous gift from Prof. M. Hamberg, Department of 
Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden. 
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3.1.2 Antibodies 
First antibodies 
 
Anti-β-actin monoclonal antibody 
produced in mouse 
Sigma-Aldrich, St. Louis, MO, USA 
Prostaglandin E synthase (cytosolic) 
polyclonal antibody, produced in rabbit 
Prostaglandin E synthase-2 (microsomal) 
polyclonal antibody produced in rabbit 
 
 
Cayman Chemical, Ann Arbor, MI, USA 
 
Prostaglandin E synthase-1 (microsomal) polyclonal antibody, produced in 
rabbit, was a kind gift from Prof. P-J Jakobsson, Department of Medical Biochemistry 
and Biophysics, Karolinska Institutet, Stockholm, Sweden. 
 
Secondary antibodies: 
 
Anti-mouse IgG, horse radish peroxidase, 
made in goat. 
Santa-Cruz Biotechnology, Santa-Cruz, Ca, 
USA 
Anti-rabbit IgG, horse radish peroxidase, 
made in goat 
Vector Laboratories, Inc, Burlingame, Ca, 
USA 
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3.1.3 Mediums and Solutions 
Medium for Caco-2 and HCT 116 cells: 
DMEM containing 4.5 g/L glucose and 25 mM Hepes, supplemented with 10% 
foetal bovine serum, 1% penicillin/streptomycin, 1% non-essential amino acids and 
1% pyruvate. 
Culture medium for PPARγ dominant-negative mutant Caco-2 cells: DMEM + 
400 µg/ml geneticin. 
 
Buffer and solutions 
DEPC-water: 0.1% DEPC solution was incubated at 37°C for 1 hour and then 
autoclaved. 
Tris-glycine buffer: 25 mM Tris, 192 mM glycine, 0.1% SDS; pH 8.3 
Blot-buffer: 25 mM Tris, 192 mM glycine, 16.5% methanol; pH 8.3 
Tween Tris Base Saline (TBS-T) buffer: 10 mM Tris/HCl, 100 mM NaCl, 
0.05% Tween-20; pH 7.5. 
Potassium phosphate buffer (0.1 M): 39 mM KH2PO4, 61 mM K2HPO4; pH 7.4 
84 mM KH2PO4, 16 mM K2HPO4; pH 6.5 
Stop solution: 25 mM FeCl2, 50mM citric acid. 
FURA-buffer: 135 mM NaCl, 4.6 mM KCl, 1.2 mM MgCl2, 1.5 mM CaCl2, 11 
mM glucose, 11 mM Hepes, 2.5 mM Probenecid; pH 7.4. 
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3.1.4 Cell lines 
Human colon cancer cell lines (Caco-2 and HCT 116) were obtained from the 
European Animal Cell Culture Collection (ECACC). 
 
Table I 
Cell line name  Morphology Description  ECACC  Nº 
Caco-2  Epithelial  Human Caucasian, well 
differentiated, colon 
adenocarcinoma. COX-1 non-
expressing cell line. 
86010202 
HCT 116  Epithelial-like Human colon carcinoma. COX-2 
non-expressing cell line. 
91091005 
 
PPARγ dominant-negative mutant Caco-2 cells were kindly provided by VK 
Chatterjee (Department of Medicine, University of Cambridge, United Kingdom) 
(Gurnell M. et al. 2000). In PPARγ dominant-negative cells the highly conserved 
hydrophobic and charged residues (Leu
468 and Glu
471) in the ligand-binding domain of 
PPARγ were mutated to alanine. This PPARγ mutant retains ligand and DNA binding, 
but exhibits markedly reduced transactivation due to impaired coactivator recruitment 
(Gurnell M. et al. 2000) 
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3.1.5 Instruments 
Autoclave Steam-Sterilizer CV-EL18L  CertoClav Sterilizer GmbH, Traun, Austria 
Bad-thermostat UC/5  Julabo Labortechnik GmbH, Seelbach, 
Germany 
Cell culture incubator BB6220  Heraeus, Hanau, Germany 
GelCamera DS-34  Polaroid, Bedfordshire, U.K. 
Gibco BRL horizontal gel 
electrophoresis apparatus Horizon 11-14 
Life technology, Carlsbad, Ca, USA 
Laminar air flow HB2448 
Megafuge 2.0, biofuge fresco 
 
Heraeus, Hanau, Germany 
Microcomputer electrophoresis 
power supply E443 
Consort, Turnhout, Belgium 
Microscope, Axiovert 135  Zeiss, Goettingen, Germany 
Mini-centrifuge “Dual-rotor”  Roth, Karlsruhe, Germany) 
Minigel electrophoresis apparatus  Biometra, Goettingen, Germany 
Multiphor II IEF electrophoresis system  Amersham Biosciences, Buckinghamshire, 
U.K. 
PerkinElmer/GeneAmp PCR system 2400  Applied Biosystems Branchburg, NJ, USA 
POLARstarOPTIMA plate reader  BMG LabTechnologies, Offenburg, Germany 
Power supply EPS301  Amersham Biosciences, Buckinghamshire, 
U.K. 
Rocking platform WT16  Biometra, Goettingen, Germany 
SLT RainBow plate reader 
SpectroFluor Plus plate reader 
 
Tecan, Maennedorf, Switzerland 
Spectrophotometer U-2000  Hitachi, Tokyo, Japan 
Thermomixer compact  Eppendorf, Hamburg, Germany 
TL 100 ultracentrifuge  Beckman Instruments GmbH, Muenchen, 
Germany 
Transilluminator Ti 1  Biometra, Goettingen, Germany 
Ultrasonic cell disruptor Microson™  SPI Supplies, West Chester, USA 
X-ray film processor Fuji FPM 800A  Fujifilm, Tokyo, Japan 
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3.1.6 Software 
GeneRunner 3.05 (Hasting Software Inc., Hasting, NY), Magellan™ comprehensive 
reader control and data reduction software (Tecan, Maennedorf, Switzerland), 
POLARstarOPTIMA software (BMG LabTechnologies, Offenburg, Germany), Desaga 
CabUVIS scanner and Desaga ProViDoc software (Desaga, Wiesloch, Germany), SigmaPlot 
2001, Microsoft Office package. 
 
 
3.2 Methods 
 
3.2.1 Cell culture 
Caco-2 and HCT 116 cells were maintained in DMEM medium containing 4.5 g/L 
glucose and 25 mM Hepes, supplemented with 10% FBS, 1% penicillin/streptomycin, 1% 
non-essential amino acids and 1% pyruvate. PPARγ dominant-negative mutant Caco-2 cells 
were cultured in the same medium, additionally containing 400 µg/ml geneticin. The medium 
was changed every second day. The cells were checked for Mycoplasma at monthly intervals. 
For experiments, 13 × 10
3 cells/cm
2 cells were seeded and incubated at 37°C, 6% CO2, 
until the cells were 40–50% confluent. The new medium with or without effectors was then 
added and the cells were incubated for the periods of time indicated. 
 
3.2.2 Cell proliferation 
Cell counting was used to evaluate proliferation by using a colorimetric assay 
following crystal violet staining (Westergren-Thorsson, G et al. 1991). The cells were seeded 
onto 96-well plates in a volume of 100 µL medium, incubated until 40–50% confluent and 
exposed to increasing concentrations of effectors. After incubation for 12-48 h, cells were 
fixed with 5% formaldehyde and the number of viable cells was evaluated by staining with 
0.05% crystal violet in 2% ethanol. After washing with phosphate buffered saline (PBS), the 
dye was extracted using citrate buffer, and the absorbance at 620 nm was measured. The 
number of cells per well was determined in comparison to a standard growth curve 
determined separately for each cell line and each experiment. 
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In a limited number of experiments, the cells were harvested by trypsinisation, stained 
with trypan blue and counted in a haemocytometer. The correlation coefficient of the results 
from both methods was 95%. 
 
3.2.3 Cytotoxicity 
Cytotoxicity was excluded by the quantification of cell death and cell lysis. The test 
was performed using a commercial lactate dehydrogenase (LDH) kit, based on the 
measurement of LDH activity released from the cytosol of damaged cells into the supernatant. 
The cell culture supernatant was collected cell-free and incubated with the reaction mixture 
from the kit. LDH enzyme activity was measured using microplate reader SLT RainBow at 
492 nm. 
 
3.2.4 Preparation of cellular fractions 
The cells were washed with cold PBS and trypsinated in 1 × trypsin/EDTA for 10 min 
at 37ºC. Thereafter, culture medium was added and cells were centrifuged at 500 × g for 10 
min followed by two washes in PBS. The cell pellets were resuspended in 1.0 ml 
homogenization buffer consisting of potassium phosphate buffer (0.1 M, pH 7.4), 1 x 
Complete
TM protease inhibitor cocktail and sucrose (0.25 M). The samples were sonicated for 
3 × 20 s at 100 W with an ultrasonic cell disruptor ( Microson™ ) and subjected to differential 
centrifugation at 1,000 × g for 10 min, 10,000 × g for 15 min and 100,000 × g for 1.5 h at 
4°C. After the last centrifugation step microsomal fractions were resuspended in 100 µL 
homogenization buffer and total protein concentration in cytosolic and microsomal fractions 
was determined by the Coomassie protein assay according to the manufacturer’s instructions. 
 
3.2.5 Analysis of mRNA levels using RT-PCR 
Cells were homogenized with RNAzol and total RNA was isolated according to the 
manufacturer's protocol. Concentration of total RNA was measured spectrophotometrically at 
260 nm (Spectrophotometer U-2000) and reverse transcription reaction was performed. 
Briefly, total RNA (1 µg) in water was heated (65°C, 12 min), slowly cooled down to 20ºC, 
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and reverse transcribed (20 min, 42°C) in PCR buffer (10 mM Tris/HCl, 50 mM KCl; pH 
8.3), containing 5 mM MgCl2, 1 mM dNTPs, 1 U × µL
-1 MuLV reverse transcriptase, 5 µM 
of oligo d(T)16, 0.5 U × µL
-1 RNase inhibitor. 
After reverse transcription, reaction samples were amplified using following 
polymerase chain reaction (PCR) mixture: cDNA in PCR buffer (10 mM Tris/HCl, 50 mM 
KCl, 1.5 mM MgCl2; pH 8.3), containing 0.2 mM dNTPs, 0.2 µM primer and 0.05 U × µL
-1 
Taq polymerase and then was denaturated 2 min at 94°C and amplified, using depicted 
primers and conditions as described in Table II (Appendix), using a PerkinElmer/GeneAmp 
PCR system 2400. 
Aliqouts of the PCR mixtures (10 µl) were analysed by electrophoresis using a 1% 
agarose gel containing 0.5 µg/ml ethidium bromide. For semi-quantitative analysis of 
amplified PCR products the fluorescent dye Pico Green
® was used according to the 
manufacturer’s instructions (Singer V. et al. 1997). 
 
3.2.6 Immunoblot analysis 
Samples were diluted and boiled for 5 min in Roti Load 1 sample buffer. Proteins were 
separated on Tris-glycine polyacrylamide gels (15% for cPGES and mPGES-1, and 12% for 
mPGES-2). After electrophoresis gels were washed in blot-buffer for 15 min to remove SDS 
and electroblotted onto nitrocellulose membranes. Transfer efficiency was visualized using 
Ponceau S stain, then membranes were washed in TBS-T buffer. Membranes were blocked 
overnight using TBS-T, and 3% non-fat dry milk. After washing the membranes with TBS-T, 
antibodies against mPGES-1, mPGES-2 and cPGES were added at a 1:1,000, 1:5,000 and 
1:500 dilution, respectively, in TBS-T and incubated for 2.5h. Membranes were incubated 
with antibodies against mPGES-1 and cPGES diluted in TBS-T buffer with 2% non-fat dry 
milk. After washing the membranes three times for 10 minutes with TBS-T, a horseradish 
peroxidase-conjugated goat antirabbit IgG was added at a 1:10,000 (mPGES-1) or 1:5,000 
(mPGES-2 and cPGES) dilution in the same buffer and incubated for 1 h and 2 h, 
respectively. The washing steps were repeated before the protein bands were visualised using 
chemiluminescence. The washed membranes were incubated for 5 min in SuperSignal
® West 
Pico Luminol/Enhancer Solution and SuperSignal
® West Pico Stable Peroxide Solution. 
Then, blots were exposed to X-ray film and developed, using a X-ray film processor. SDS-
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PAGE immunoblots were quantitated by scanning densitometry, using a Desaga CabUVIS 
scanner and Desaga ProViDoc software. 
 
3.2.7 PGES enzyme assay 
PGES enzyme activity was determined according to Thoren S. et al. 2000. Microsomal 
or cytosolic fraction samples were diluted in potassium phosphate buffer (0.1 M, pH 6.5) 
containing 0.5 mM dithiothreitol (DTT). PGH2 (4 µl) dissolved in acetone (0.28 mM) was 
kept in separate vials at -80 °C. Prior to incubation, both the substrate and samples were 
equilibrated at 4 °C for 2 min. The reaction was started by the addition of the sample to the 
tubes containing PGH2 (final concentration 10 µM) and then terminated by adding stop 
solution lowering the pH to 3, giving a total concentration of 20 mM FeCl2 and 40 mM citric 
acid. The reaction mixture was then diluted in EIA buffer and assayed
 for PGE2 using an 
enzyme immunoassay kit. The assay is based on the competition between PGE2 and PGE2-
acetylcholinesterase conjugate for a limited amount of PGE2 monoclonal antibody. The 
antibody-PGE2 complex bound to goat polyclonal anti-mouse IgG and substrate for 
acetylcholinesterase was added. The absorbance was determined using 5,5’-dithio-bis-(2-
nitrobenzoic acid) at 412nm. 
 
3.2.8 Measurement of intracellular calcium level 
Measurement of intracellular calcium was performed according to (Sabirsh A. et al. 
2003). Caco-2, HCT 116 and Caco-2 PPARγ dominant-negative mutant cells were seeded 
onto black, clear bottomed 96-well plates (Greiner bio-one, Kremsmuenster, Austria). The 
plates were incubated for 4-5 days at 37°C, 6% CO2, until the cells were 80–90% confluent. 
The growth medium was then exchanged for growth medium without FBS containing 4 µM 
Fura-2 acetoxymethyl ester (Fura-2-AM), 2.5 mM Probenecid; the cells were incubated for 1 
h at 37°C and 6% CO2. After that loading time, the cells were washed four times with 50 µl of 
FURA-buffer to remove free FURA-2AM. A final 50 µl volume of FURA-buffer was added 
to each well. Fluorescence was monitored following 120 s using a fluorometer 
POLARstarOPTIMA, after injection of 50 µl of buffer or solution containing test substances. 
The ratio of emitted fluorescence, following stimulation by 340- and 380-nm light, was 
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calculated following background subtraction at each wavelength. Cells not exposed to FURA-
2 were used to subtract background auto-fluorescence. 
 
3.2.9 Statistics 
If not otherwise stated, data are expressed as means ± SEM of three independent 
experiments performed in duplicate. Data were analysed by one-way ANOVA (analysis of 
variance) and Student’s t test. P < 0.05 was considered to be statistically significant. 
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4. Results 
 
 
4.1. 15d-PGJ2 down-regulates mPGES-2 gene and protein expression 
 
4.1.1 Effect of 15d-PGJ2 on gene expression of the enzymes of prostaglandin E2 
synthesis 
Since cyclooxygenases and prostaglandin E synthases are known to be involved in 
colon cancer development and progression, the possible effect of 15d-PGJ2, on the mRNA 
expression of these enzymes was first assayed. HCT 116 and differentiated Caco-2 cells were 
treated with increasing concentrations of 15d-PGJ2 from 0.1 to 40 µM and cells were 
incubated during 4 hours. 
Total RNA was isolated from samples and RT-PCR was performed. The amount of 
PCR products was examined using the Pico Green dsDNA quantitation kit. As a control of 
mRNA expression of target genes house-keeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was analysed. Fig. 7A and B depict an expression of COX and 
PGES mRNA in Caco-2 and HCT 116 colon cancer cell lines. The levels of cPGES, mPGES-
1, COX-1 (expressed in HCT 116) and COX-2 (expressed in Caco-2) remained unchanged 
following treatment with this cyclopentenone, while the expression of mPGES-2 mRNA was 
down-regulated by 15d-PGJ2 in both cell lines tested. The effect of 15d-PGJ2 on mPGES-2 
mRNA levels was dose dependent. HCT 116 cells were more sensitive to 15d-PGJ2 than 
Caco-2 cells; the 50% inhibition of mRNA expression was at 5 µM concentration of 15d-PGJ2 
for HCT 116 and at 10 µM for Caco-2 cells. Concentrations above 40 µM led to the death of 
HCT 116 cells within 4 hours of incubation. 
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Fig. 7. Inhibition of mPGES-2 mRNA expression by 15d-PGJ2 in the colorectal 
cancer cell lines Caco-2 and HCT 116. Caco-2 (A) and HCT 116 (B) cells were incubated 
for 4 h in the absence or presence of indicated concentrations of 15d-PGJ2. RT-PCR was 
performed on total RNA for COX-2, COX-1, mPGES-1, mPGES-2, cPGES, and GAPDH 
during the linear phase of amplification. All values for mRNA are normalized to the 
corresponding mRNA amount for GAPDH. 
 
 
The concentrations of 15d-PGJ2 induced 50% reduction of mPGES-2 mRNA 
expression were then used for a time course analysis. Colon cancer cells were treated with 
15d-PGJ2 for different time intervals, from 1 to 24 hours. (HCT 116 cells were stimulated 
with 5 µM and Caco-2 with 10 µM 15d-PGJ2). mPGES-2 mRNA expression was analysed as 
described above. As shown in Fig. 8, 15d-PGJ2 transiently inhibited mPGES-2 mRNA 
expression with a maximal suppression at 4 hours for both cell lines. 
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Fig. 8. Transient effect of 15d-PGJ2 on mPGES-2 mRNA expression in the 
colorectal cancer cell lines Caco-2 and HCT 116. Time course of mPGES-2 mRNA 
expression in Caco-2 (black bars) cells treated with 10 µM of 15d-PGJ2 and HCT 116 (white 
bars) cells stimulated with 5 µM of 15d-PGJ2 for indicated incubation periods. Total RNA 
was isolated as described in the method section and subjected to semi-quantitative RT-PCR 
by the fluorescent dye PicoGreen
®. All values for mRNA are normalized to the corresponding 
mRNA amount for the housekeeping gene GAPDH. The statistical significance of changes 
relative to untreated controls is expressed: **P < 0.01, ***P < 0.001. 
 
 
4.1.2 15d-PGJ2 decreases mPGES-2 protein expression 
To determine if the reduction of mPGES-2 mRNA level correlated with decreases in 
protein expression cell lines were treated with 1 and 10 µM 15d-PGJ2 for various time 
intervals. Since recent work by Murakami M. et al. could demonstrate that mPGES-2 is 
synthesized as a Golgi membrane-associated protein, and then additionally distributed in the 
cytosol with local enrichment in the perinuclear region, the subcellular distribution of this 
enzyme in response to 15d-PGJ2 was also determined. Cell lysate was divided in microsomal 
and cytosolic fractions and the amount of mPGES-2 protein was analysed by immunoblotting 
as described in the method section. The intensity of protein spots was quantitated by scanning 
densitometry, using a Desaga CabUVIS. As a control of protein expression, the expression of 
the house-keeping gene β-actin was analysed. 
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As shown in Fig. 9, at a concentration of 1 µM 15d-PGJ2, the suppressive effect on 
protein expression in HCT 116 was observed as early as 12 h after treatment, whereas in the 
Caco-2 cell line reduction of mPGES-2 protein expression only occurred after an incubation 
period of 36 h. At later time points, protein level gradually returned to baseline levels. When 
incubated with 10 µM 15d-PGJ2, transient suppression of protein reached its maximum 
already at 6 h for HCT 116 and 12 h for Caco-2. 
 
 
Fig. 9. Down-regulation of mPGES-2 protein expression by 15d-PGJ2 in Caco-2 
and HCT 116 cells. Western blot analysis of mPGES-2 protein expression in Caco-2 and 
HCT 116 cells incubated in the presence of 1 and 10 µM 15d-PGJ2 for the times indicated. In 
all lanes, 15 µg of protein from the microsomal fraction of cells was analyzed. The results 
shown are representative of three separate experiments performed in duplicate. 
 
 
mPGES-2 could be detected in both, the cytosolic and membrane fraction. As 
demonstrated in Fig. 10, the concentration of mPGES-2 protein remained unchanged in 
cytosolic fraction. 
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Fig. 10. mPGES-2 protein distribution in the response to 15d-PGJ2. Western blot 
analysis of mPGES-2 protein expression in Caco-2 and HCT 116 cells incubated in the 
absence and presence of 10 µM 15d-PGJ2 for the times indicated. In all lanes, 15 µg of 
protein from the cytosolic fraction of cells was analyzed. The results shown are representative 
of three separate experiments performed in duplicate. 
 
 
In contrast, no distinct mPGES-1 protein could be detected in either cell line. As 
shown in Fig. 11, treatment of cells with 10 µM 15d-PGJ2 did not evoke any change in 
cPGES protein level. 
 
Fig. 11. The effect of 15d-PGJ2 on cPGES protein expression. Western blot analysis 
of mPGES-2 protein expression in HCT 116 cells incubated in the absence and presence of 10 
µM 15d-PGJ2 for the times indicated. In all lanes, 15 µg of protein from the cytosolic fraction 
of cells was analyzed. The results shown are representative of two separate experiments 
performed in duplicate. Similar results were also obtained in Caco-2 cells (data not shown). 
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4.1.3 15d-PGJ2 reduces mPGES-2 enzyme activity 
To confirm that down-regulation of mPGES-2 gene and protein expression leads to a 
decrease in PGE2 production, Caco-2 and HCT 116 cells were treated with 10 µM 15d-PGJ2 
for 12 hours. Thereafter, cells were lysed, divided on fractions and PGES enzyme activity in 
both, cytosolic and microsomal fractions was determined. The amount of produced PGE2 was 
140 ng/min/mg protein in cytosolic fraction and about 20 ng/min/mg in microsomal fraction. 
The relative amount of activity as compared with control is depicted at Fig. 12. 
 
 
 
 
Fig. 12. Dependence of PGES activity in the microsomal and cytosolic fraction by 
15d-PGJ2 in the colorectal cancer cell lines Caco-2 and HCT 116. Caco-2 and HCT 116 
cells were treated with 10 µM 15d-PGJ2 for 12 h. Cytosolic and microsomal fractions were 
separated and enzymatic activity was performed as described in the experimental procedures. 
The relative amount of activity as compared with control in Caco-2 (black bars) and HCT 
116 (white bars) is depicted. Mean ± SEM of three independent experiments performed in 
triplicate are plotted. The statistical significance of changes relative to unstimulated controls 
is expressed: *P < 0.05, **P < 0.01. 
 
 
In accordance to the down-regulation of the mPGES-2 on the gene and protein level, a 
substantial decrease in enzyme activity could be noticed upon treatment with 15d-PGJ2. 
Enzymatic activity was only found to be reduced in the microsomal fraction, while in the 
cytosolic fraction the activity remained unchanged. The notably discrepancy in microsomal 
mPGES-2 activity reduction between both cell lines may be explained, most likely, by a 
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different sensitivity of HCT 116 and Caco-2 to 15d-PGJ2, as already reflected in the gene 
expression studies. 
 
 
4.2. 15d-PGJ2 does not act via PPARγ or PGD receptors but may cause 
oxidative stress and covalent modification of proteins 
 
4.2.1 Decreased expression of mPGES-2 in response to 15d-PGJ2 treatment is 
PPARγ independent 
Since 15d-PGJ2 has long been established a natural ligand of PPARγ we examined 
whether another PPARγ agonist – the thiazolidinedione homolog MCC555 may also reduce 
mPGES-2 expression. Since the most efficient concentration of MCC555 necessary to 
activate PPARγ was described to be 50 µM (Reginato M. et al. 1998), this concentration was 
used to treat differentiated Caco-2 cells and HCT 116 cells. Cells were then cultured for 
various incubation periods (0-24 h). Total RNA was isolated from samples and RT-PCR was 
performed as described earlier. All values for mRNA were normalized to the corresponding 
mRNA amount for the housekeeping gene GAPDH. No changes in mRNA expression of 
mPGES-2 or any of the other enzymes examined (COX-1, COX-2, mPGES-1 and cPGES) 
were observed upon treatment with MCC555. The effect of MCC555 on mRNA expression of 
COX and PGES enzymes is summarized in Fig. 13A and B. 
This observation suggested that the effect of 15d-PGJ2 on mPGES-2 expression might 
be independent of PPARγ. 
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Fig. 13. The effect of the thiazolidinedione homolog MCC555, a synthetic PPARγ 
agonist, on COX and PGES mRNA expression. Caco-2 (A) and HCT 116 (B) cells were 
incubated with 50 µM MCC555 for indicated incubation periods. RT-PCR was performed on 
total RNA for COX-2, COX-1, mPGES-1, mPGES-2, cPGES, and GAPDH during the linear 
phase of amplification. All values for mRNA are normalized to the corresponding mRNA 
amount for GAPDH. The statistical significance of changes in mPGES-2 mRNA expression 
relative to untreated controls is P < 0.001. 
 
 
To further confirm this hypothesis, Caco-2 PPARγ dominant-negative mutant cells 
were subjected to 15d-PGJ2 treatment. The same concentrations as for HCT 116 and Caco-2 
cells in previous experiments (5, 10, 20, 40 µM) were used. Cells were incubated for 4 hours 
and mRNA expression of COX-2, mPGES-1, cPGES and mPGES-2 was analysed. As it 
shown in Fig. 14, the levels of cPGES, mPGES-1 and COX-2 remained unchanged following 
treatment with 15d-PGJ2, while the expression of mPGES-2 mRNA was reduced to a similar 
extent when compared with the non-transfected Caco-2 cell line or HCT 116 cells. The 50% 
inhibition of mRNA expression was at 10 µM concentration of 15d-PGJ2, similar to the 
results obtained with non-transfected Caco-2 cells. 
 
  40   RESULTS 
 
 
 
Fig. 14. Inhibition of mPGES-2 mRNA expression by 15d-PGJ2 in PPARγ 
dominant-negative mutant Caco-2 cells. PPARγ dominant-negative mutant Caco-2 cells were 
treated for 4 h in the absence or presence of indicated concentrations of 15d-PGJ2. RT-PCR 
was performed on total RNA for COX-2, mPGES-1, mPGES-2, cPGES, and GAPDH during 
the linear phase of amplification. All values for mRNA are normalized to the corresponding 
mRNA amount for GAPDH. The statistical significance of changes relative to untreated 
controls is expressed: **P < 0.01, ***P < 0.001. 
 
 
Additionally, the protein expression of mPGES-2 was determined. Caco-2 PPARγ 
dominant-negative mutant cells were incubated with 10 µM 15d-PGJ2 for 12-36 h and protein 
amount in microsomal and cytosolic fractions were analysed by immunoblotting. The 
suppressive effect on protein expression was observed at 12-24 hours after treatment, as 
illustrated in Fig. 15, similar to the results obtained with Caco-2 non-transfected cells. At later 
time points, protein level gradually returned to baseline levels. In contrast, the concentration 
of mPGES-2 protein remained unchanged in cytosolic fraction. 
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Fig. 15. Inhibition of mPGES-2 protein expression by 15d-PGJ2 in PPARγ 
dominant-negative mutant Caco-2 cells. Immunoblot analysis of mPGES-2 protein 
expression in PPARγ dominant-negative mutant Caco-2 cells incubated in the absence and 
presence of 10 µM 15d-PGJ2 for the times indicated. The top panel shows a series of 
immunoreactive bands corresponding to mPGES-2 and β-actin (serving as an internal 
control). The bottom panel depicts a histogram obtained by densitometric analysis of 
immunoblots from three independent experiments normalized to protein expression of β-actin. 
The statistical significance of changes relative to untreated controls is expressed: **P < 0.01. 
 
 
PGES enzyme activity was also assayed in Caco-2 PPARγ dominant-negative mutant 
cells. The relative amount of PGE2 produced by PGES after treatment with 10 µM 15d-PGJ2 
for 12 hours in microsomal and cytosolic fraction is shown in Fig. 16. Similar reduction of 
PGE2 production could be detected if compared to Caco-2 non-transfected cells. A strong 
decrease of the enzyme activity in the microsomal fraction was observed, while in the 
cytosolic fraction the activity remained unchanged. 
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Fig. 16. Dependence of PGES activity in the microsomal and cytosolic fraction by 
15d-PGJ2 in PPARγ dominant-negative mutant Caco-2 cells.  PPARγ dominant-negative 
mutant Caco-2 cells were treated with 10 µM 15d-PGJ2 for 12 h. Cytosolic and microsomal 
fractions were separated and enzymatic activity was performed as described in the 
experimental procedures. The relative amount of activity as compared with control is 
depicted. Mean ± SEM of two independent experiments performed in triplicate are plotted. 
The statistical significance of changes relative to unstimulated controls is expressed: **P < 
0.01. 
 
 
4.2.2 15d-PGJ2 does not affect mPGES-2 expression via cell surface receptors 
15d-PGJ2 can exert its action on cell metabolism via binding to the PGD2 receptors 
DP1 and CRTH2 (Powell W. 2003). DP1 activation by PGD2 leads to the stimulation of 
adenylyl cyclase activity and an increase in intracellular cAMP levels, while CRTH2 
activation by PGD2 leads to an increase in intracellular calcium mobilization. 
An activation of CRTH2 receptor by 15d-PGJ2 have been examined measuring 
intracellular calcium levels, as illustrated in Fig. 17. Cells were loaded with the calcium 
sensitive fluorescent dye FURA-2AM and the effects of 15d-PGJ2 on intracellular calcium 
levels in Caco-2, HCT 116 and Caco-2 PPARγ dominant-negative mutant cells, were 
compared with those of PGD2 and another cyclopentenone prostaglandin PGA2. Different 
concentrations of agonist (from 1 to 10 µM) were used. In repeated experiments neither 15d-
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PGJ2 and PGA2 nor PGD2 stimulated calcium mobilization. The cells did, however, respond 
normally to ATP, positive control. 
 
Fig. 17. The regulation of mPGES-2 expression by 15d-PGJ2 is not mediated via 
CRTH2 receptor activation. Course of [Ca
2+]i in Fura-2/AM loaded HCT 116 cells. Cells 
were challenged with 10 µM 15d-PGJ2 (+) or 10 nM ATP (), serving as a positive control. 
Representative data from three experimental observations are given. Similar results were also 
obtained with 15d-PGJ2 in Caco-2 cells as well as with PGA2 and PGD2 in both, Caco-2 and 
HCT 116 cells (data not shown).  
 
 
Given that activation of the other PGD2 receptor, DP1, leads to an increase in 
intracellular cAMP levels, the effect of increasing intracellular cAMP levels on mPGES-2 
protein expression was tested. HCT116 cells were treated with 10 and 100 µM forskolin 
(Yang F. et al. 2004; Ostrom R. et al. 2001), which directly stimulates adenylyl cyclase and 
thus increases intracellular cAMP levels. Cells were cultured for 12-36 h, when the most 
intense protein expression inhibition by 15d-PGJ2 was observed. However, Fig. 18 
demonstrates that mPGES-2 protein expression was not affected following the treatment with 
various concentrations of forskolin. 
 
 
  44   RESULTS 
 
 
Fig. 18. The regulation of mPGES-2 expression by 15d-PGJ2 is not mediated via 
DP1 receptor activation. Immunoblot analysis of mPGES-2 protein expression in HCT 116 
cells in response to forskolin, which directly activates adenyl cyclase as an indication of DP1 
receptor activation, for the various concentrations and times indicated. The results shown are 
representative of two independent experiments. Identical results were also observed in Caco-
2 cells (data no shown). 
 
 
These experiments revealed that the effect of 15d-PGJ2 on mPGES-2 expression is 
independent of PGD2 receptor activation in HCT 116 and Caco-2 colon cancer cells. 
 
4.2.3 The role of cyclopentenone ring structure in the down-regulation of 
mPGES-2 expression 
To verify or exclude a selective effect of 15d-PGJ2 on mPGES-2, HCT 116, Caco-2 
and Caco-2 dominant negative PPARγ mutant cells were treated with similar concentrations 
(1, 10, 20 µM) of another cyclopentenone prostaglandin, PGA2. Cells were incubated for 12-
36 hours and protein level in microsomal and cytosolic fractions was analysed by 
immunoblotting. PGA2 displayed a similar inhibitory effect on mPGES-2 protein expression. 
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Fig. 19. Effect of arachidonic acid, 
PGA2, and PGD2 on mPGES-2 protein 
expression. Caco-2 (A), HCT 116 (B) and 
PPARγ dominant-negative mutant Caco-2 
(C) cells were incubated for 12 h in the 
presence or absence of indicated 
eicosanoids used in various 
concentrations. Western blot analysis was 
performed as described in the experimental 
procedure section. The results in each top 
panel show a series of immunoreactive 
bands corresponding to mPGES-2. β-actin 
served as an internal control. The bottom 
panels depict a histogram obtained by 
densitometric analysis of the immunoblots 
in each cell line from three independent 
experiments normalized to protein 
expression of β-actin. The statistical 
significance of changes relative to 
untreated controls is expressed: *P < 0.05, 
**P < 0.01. 
  46   RESULTS 
The minimal effective concentration was found to be 1 µM in either, Caco-2 (Fig. 
19A), HCT 116 (Fig. 19B) or Caco-2 dominant negative PPARγ mutant cells (Fig. 19C). The 
significant reduction in protein level was observed at 12 hours, whereas at 24 and 36 hours 
the protein concentration almost returned to baseline levels (Fig. 20). Concentrations above 
20 µM led to cell death. 
 
 
 
Fig. 20. Effect of PGA2 on mPGES-2 protein expression. Caco-2, HCT 116 and 
PPARγ dominant-negative mutant Caco-2 cells were treated with different concentration of 
PGA2 (1 and 10 µM) during 12-24 hours, as indicated. In all lanes, 15 µg of protein from the 
microsomal fraction of cells was analyzed. The results shown are representative of three 
separate experiments performed in duplicate. 
 
 
To ascertain whether the effect of prostaglandins on mPGES-2 expression is specific 
for cyclopentenones the cells were also treated with 10 and 50 µM PGD2 and with 10 and 30 
µM AA and incubated for the same period of time (12-36 h). In contrast to 15d-PGJ2 and 
PGA2, no change in mPGES-2 protein expression upon treatment with AA and PGD2 could 
be observed (Fig. 19A, B, C). 
Similar results were also obtained with leukotrienes (LT) in HCT 116 cells. Cells were 
treated with 10 nM LTB4 or 100 nM LTD4 for 12-36 hours. No changes in mPGES-2 protein 
concentration were observed, as presented in Fig. 21. 
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Fig. 21. Effect of leukotrienes on mPGES-2 protein expression. HCT 116 cells were 
treated with 10 nM LTB4 and 100 nM LTD4 during 12-36 hours, as indicated. In all lanes, 15 
µg of protein from the microsomal fraction of cells was analyzed. The results shown are 
representative of three separate experiments performed in duplicate. Similar results were also 
obtained with LTB4 and LTD4 in Caco-2 cells. 
 
 
4.2.4 Cyclopentenone prostaglandins induce oxidative stress 
Cyclopentenone prostaglandins have been demonstrated to modulate gene expression 
via mechanisms involving oxidative stress; therefore the role of oxidative stress in mPGES-2 
expression inhibitions was next studied. Caco-2 and HCT 116 cells were pretreated with or 
without antioxidants: 2 mM dithiothreitol (DTT) or 5-30 mM N-acetylcysteine (NAC), for 2 
hours. Then cells were stimulated with 15d-PGJ2 for the next 12 hours and protein level in 
microsomal and cytosolic fractions was analysed by immunoblotting. As shown in Fig. 22 
and 23, 15d-PGJ2 mPGES-2 protein expression inhibition was completely reversed by 
antioxidants and this effect was dose dependent. At concentrations of NAC higher than 5 mM 
even an upregulation of mPGES-2 protein could be observed. 
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Fig. 22. Influence of antioxidants on the inhibitory effects of 15d-PGJ2 on mPGES-
2 expression in colorectal cancer cells. Caco-2 (upper panel) and HCT 116 (bottom panel) 
cells were pretreated for 2 h in the presence or absence of 30 mM NAC or 2 mM DTT. Then 
cells were stimulated with 10µM 15d-PGJ2 for the next 12 h. Protein amount was analyzed 
using immunoblotting of 15 µg protein from the microsomal fraction of cells with β-actin 
serving as an internal control. The results shown are representative of three separate 
experiments. 
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Fig. 23. Influence of different concentration of antioxidant on the inhibitory effects 
of 15d-PGJ2 on mPGES-2 expression in colorectal cancer cells. HCT 116 cells were 
pretreated for 2 h in the presence or absence of 5, 15 and 30 mM NAC. Then cells were 
stimulated with 10 µM 15d-PGJ2 for the next 12 h. Protein amount was analyzed using 
immunoblotting of 15 µg protein from the microsomal fraction of cells with β-actin serving as 
an internal control. The results shown are representative of three separate experiments. 
 
 
 
To further confirm the role of oxidative stress in mPGES-2 expression inhibition, HCT 
116 and Caco-2 cells were subjected to 10 and 100 µM H2O2. Hydrogen peroxide is one of 
reactive oxygen species, which causes oxidative damage. Cells were incubated during 12-36 
hours and protein level was analysed by immunoblotting. However, as presented in Fig. 24, 
oxidative stress induced by H2O2 did not affect mPGES-2 protein expression. 
This may suggest that NAC or DTT bind 15d-PGJ2, thereby preventing its impact on 
cellular target proteins or that exogenous hydrogen peroxide does not completely reproduce 
intracellular oxidative stress induced by 15d-PGJ2. 
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Fig. 24. The effect of H2O2 induced oxidative stress on mPGES-2 expression in 
colorectal cancer cells. HCT 116 cells were treated with different concentration of H2O2 (10 
and 100 µM) during 6-36 hours, as indicated. In all lanes, 15 µg of protein from the 
microsomal fraction of cells was analyzed. The results shown are representative of two 
separate experiments performed in duplicate. Identical results were also observed in Caco-2 
cells (data no shown). 
 
 
4.3 The role of mPGES-2 gene, protein and enzyme activity down-
regulation in the colon cancer cell growth 
 
4.3.1 The effect of 15d-PGJ2 on cell growth 
In order to investigate the role of mPGES-2 gene, protein and enzyme activity down-
regulation by 15d-PGJ2 in colon cancer cell growth, cell proliferation was analysed. HCT 116 
cells were stimulated with 0.1, 1, 5, 10, 20 and 40 µM 15d-PGJ2 in DMEM, containing 10% 
FBS. Since serum provides a broad spectrum of macromolecules including hormones and 
growth factors, which essentially positively affect cell growth; two controls were performed: 
cells grown in medium with or without FBS. 0,1 and 1 µM 15d-PGJ2 had no significant effect 
on cell growth, whereas 5 µM 15d-PGJ2 and 10 µM 15d-PGJ2, demonstrated in Fig. 25, 
induced 20-30% and 40 – 67% reduction in cell amount at 24 – 48 h, respectively. 20 and 40 
µM concentrations led to cell death after 24 hours of incubation. 
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Fig. 25. Anti-proliferative effect of 15d-PGJ2 on colon cancer cell growth. HCT 116 
cells (2 × 10
4/well) were placed in 96-well plates, grown in DMEM medium with 10% FBS 
until 40–50% confluent and then incubated in medium with or without 5 and 10 µM 15d-PGJ2 
for indicated time periods. After the end of experiment the number of viable cells was 
evaluated by staining with 0.5% crystal violet in 2% ethanol. The results were normalised to 
the amount of cells before stimulation. The statistical significance of changes relative to 
untreated controls is expressed: ***P < 0.001. 
 
 
The rate of proliferation after stimulation with 10 µM 15d-PGJ2 was comparable to 
cells grown in serum free medium. 
 
4.3.2 The implication of PGE2 formation in cell proliferation 
As previously mentioned, both 15d-PGJ2 and PGA2 have been shown to decrease 
growth of cancer cells in vitro. Therefore the influence of PGA2 on cell proliferation in the 
HCT 116 cell line as well as the potential involvement of the inhibition of mPGES-2 in the 
anti-proliferative effect of cyclopentenone prostaglandins was evaluated. HCT 116 cells were 
stimulated with 10 µM PGA2 in DMEM, containing 10% FBS. As illustrated in Fig. 26A, 
exogenously added PGA2 exerted a growth-inhibitory effect on HCT 116 cells, which resulted 
in a 20 – 30% reduction in cell amount at 24 – 48 h, respectively. At comparable 
concentrations the growth-inhibitory effect of PGA2 was less potent than that of 15d-PGJ2. 
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Fig. 26. Anti-proliferative effect of PGA2 on colon cancer cell growth. (A) HCT 116 
cells (2 × 10
4/well) were placed in 96-well plates, grown until 40–50% confluent and then 
incubated in medium with or without 10 µM PGA2 for indicated time periods. After the end of 
experiment the number of viable cells was evaluated by staining with 0.5% crystal violet in 
2% ethanol. The results were normalised to the amount of cells before stimulation. (B) 
Undifferentiated HCT 116 cells (2 × 10
4/well) were first treated with 10 µM PGA2 for 24 h. 
Pretreated cells were then further stimulated with either 1 nM PGE2 (grey bars) or 10 µM 
PGA2 (white bars) and analysed at time points 0, 24 h and 48h (corresponding to 24, 48, and 
72 h after the first addition of PGA2). In parallel, control cells (black bars) that had not been 
pretreated with PGA2, were stimulated with vehicle alone. Cell count was performed as 
indicated above and plotted after normalisation to the amount of cells before stimulation. The 
statistical significance of changes relative to untreated controls is expressed: **P < 0.01, 
***P < 0.001. 
 
 
 
As evident from Fig. 26B pre-treatment of HCT 116 with 10 µM PGA2 for 24 h, and 
subsequent addition of 0.1-10 nM PGE2 to the medium for up to 48 h completely abolished 
the anti-proliferative action of PGA2, indicating, that down-regulation of mPGES-2 followed 
by reduced PGE2 biosynthesis at least in part contributed to the anti-proliferative action of 
cyclopentenone prostaglandins in HCT 116. 
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5. Discussion 
 
5.1 The role of mPGES-2 in colon cancer and its down-regulation by anti-tumour 
cyclopentenone prostaglandin, 15d-PGJ2. 
 
Colorectal cancer is ranked the third most common form of cancer worldwide in terms 
of incidence (9.4% of the world total) and mortality (7.9% of the total) (Brown et al. 2005). 
Interest in COX as a therapeutic target for colorectal cancer derives from epidemiologic 
studies that have consistently shown a 40–50% reduction in colon cancer incidence among 
chronic users of NSAIDs (Thun M. et al 1991; Sinicrope F et al. 2004) and the most 
important mechanism by which NSAIDs exert their anti-neoplastic effects is thought to be the 
inhibition of COX-2 activity. COX-2, but not COX-1, has also been shown to be 
overexpressed in an estimated 40% of human colorectal adenomas and 80% of 
adenocarcinomas compared to normal epithelial cells (Eberhart C. et al. 1994; Elder D. et al. 
2002; Hao X. et al 1999). COX catalyze the conversion of AA to PGG2 and PGH2, which is 
subsequently enzymatically converted to a variety of PG. Studies on the roles of the various 
PG that act downstream of COX-2 during the development and progression of colorectal 
cancer clearly have established that PGE2 is the major, if not only, PG implicated in colorectal 
cancer. Elevated levels of PGE2 have been shown in colorectal cancer in vivo (Rigas B. et al. 
1993; Pugh S. et al. 1994). The effects of exogenous PGE2 on intestinal polyp formation in 
Min mice, which possess a germ line mutation in the Apc gene and
 are employed as a model 
of familial adenomatous polyposis in humans was also documented (Wilson J. et al. 2000; 
Hansen-Petrik M. et al. 2002). In addition, several in vitro reports have demonstrated that 
PGE2 induces cell proliferation (Sheng H. et al. 2001), inhibits apoptosis (Sheng H. et al. 
1998) as well as promotes motility and angiogenesis (Sheng H. et al. 2001; Fukuda R. et al. 
2003). 
Among the three known proteins capable to isomerise PGH2 to PGE2, mPGES-1 and 
mPGES-2 were found to be markedly increased in colorectal cancer tissues (Rees, B et al. 
2003; Murakami M. et al. 2003). mPGES-1 and COX-2 are coexpressed in malignant and 
benign colorectal tumour cells and are involved in PGE2 production and cell proliferation in 
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vitro. This effect was attributed to changes in the expression of a variety of genes related to 
proliferation and differentiation, transcriptional factors, genes related to
  cytoskeletal 
regulation and cell adhesion molecules (Kamei D. et al. 2003). However, until now no such 
information is available for mPGES-2. 
As already pointed out, mPGES-1 and COX-2 enzymes are co-localized in the 
perinuclear envelope and functionally coupled. Coupling between COX-1 and mPGES-1 
occurs only when a large amount
 of AA is supplied exogenously, or if burst activation of 
cPLA2 takes place, endogenously. (Murakami M. et al. 2000). In contrast, mPGES-2 is 
synthesized as a Golgi membrane-associated protein. Thereafter, spontaneous cleavage of the 
mPGES-2 N-terminal hydrophobic domain leads to the formation of a truncated mature 
protein, which is distributed in the cytosol with local enrichment in the perinuclear region 
(Murakami M. et al. 2003). Because of such simultaneously localisation in the cytosol and 
perinuclear envelope, mPGES-2 can promote PGE2 production via both, COX-2 and COX-1 
proteins, which has been demonstrated by Murakami M et al (2003). 
Several reports have also demonstrated that gene expression of mPGES-1 and COX-2 
are co-regulated (Murakami M. et al. 2000; Yoshimatsu K. et al. 2001; Shinji Y et al 2005). 
However, in several cases COX-2 and mPGES-1 expression is not regulated by the same 
pathway (Rees B. et al. 2003; Devaux Y. et al. 2001; Masuko-Hongo K. et al. 2004) In 
contrast, expression of cPGES has been postulated to be linked with COX-1 (Tanioka T. et al. 
2000). Coupling of COX-2 and mPGES-2 expression may also occur since decreased protein 
expression of mPGES-2 in COX-2
-/- mice has been described (Bosetti F. et al. 2004). Based 
on these data PGES expression in cell lines with different COX-isoform phenotype: Caco-2 
cells, which do not express COX-1 and HCT 116 cells that are not capable to produce COX-2 
was examined to reveal a possible coregulation of PGES and COX enzymes. 
Recent findings unravelled the role of the 15d-PGJ2 as a potent anti-tumoral agent. 
The role of apoptosis and growth inhibition caused by 15d-PGJ2 in a number of cell types, 
including endothelial cells, bone marrow-derived cells such as macrophages and lymphocytes 
and many tumour cells, has been evaluated. However, the apoptotic signalling pathways that 
are related to the 15d-PGJ2 are still poorly understood (Shimada T. et al. 2002; Vanaja D. et 
al. 2000, Emi M. et al. 2004). The inhibition of cell growth and induction of apoptosis by this 
compound in gastric cancer cells was accompanied by a decrease in COX-2 mRNA and 
protein expression as well as in PGE2 production (Chen Y. et al. 2003). Changes in PGE2 
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biosynthesis occurred prior to apoptosis, suggesting that down-regulation of COX-2 might be 
an upstream event of 15d-PGJ2-induced cell growth inhibition and apoptosis. mPGES-1 
activity was also shown to be inhibited by 15d-PGJ2 (Quraishi O. et al. 2002). There is also 
some evidence, pointing out a link between PG biosynthesis and 15d-PGJ2 i n  f o r m  o f  a  
feedback control of COX-2 by this PG metabolite (Inoue H. et al. 2000; Tsubouchi Y. et al. 
2001). Additionally to these reports, 15d-PGJ2 was found to regulate many transcriptional 
factors and signalling molecules related to cell cycle regulation and apoptosis including those 
controlled COX-2 and mPGES-1 expression. 15d-PGJ2 modulates the expression and activity 
of p53 (Shan Z. et al. 2004), NF-κB (Rossi A. et al. 2000), JNK (Liu J. et al. 2003), PPARγ 
(Forman B. et al. 1995), H-RAS ( Oliva J. et al. 2003), Egr-1, Egr-3, HSP70 (Cippitelli M. et 
al. 2003). Together these data provide a hypothesis that 15d-PGJ2 may be a potential regulator 
not only of COX but also PGES enzymes that could unravel a novel mechanism for the anti-
proliferative effects of this compound. 
In our study we sought to determine the potential implication of this cyclopentenone 
prostaglandin in PGE2 mediated colorectal cancer promotion and PGES gene expression 
regulation. It was found that 15d-PGJ2 selectively down-regulated mPGES-2 in the colorectal 
cancer cell lines Caco-2 and HCT 116 without affecting any other terminal PGES or COX. 
Inhibition of mPGES-2 mRNA expression was time- and dose-dependent and reduction in 
gene expression was followed by a time delayed decrease in mPGES-2 protein levels. The 
effect of 15d-PGJ2 on mPGES-2 expression was transient. 
To investigate the possible co-regulation of mPGES-2 with COX-2 or COX-1 colon 
cancer cells with different COX-isoform phenotype were treated with 15d-PGJ2. Both cell 
lines displayed similar down-regulation of mPGES-2 gene and protein expression upon 
challenge with 15d-PGJ2. COX-1 and COX-2 expression levels yet remained unaffected, 
indicating that the inhibitory effect of 15d-PGJ2 on mPGES-2 is independent of COX-1 or 
COX-2 expression. mPGES-1 protein was not detected in our cell lines eliminating its role in 
metabolism and physiology of the cell lines analysed. 
10 µM concentration of 15d-PGJ2 induced reduction of mPGES-2 protein amount 
already at 6-12 hours, whereas 1 µM concentration was also efficient but on later time points, 
(Fig. 9, chapter 4). This suggests that little concentrations of 15d-PGJ2 may reproduce the 
effect of high concentrations on mPGES-2 protein expression but longer incubation period are 
required. The reduction of mPGES-2 protein amount was observed only in the microsomal 
  56   DISCUSSION 
fraction, whereas it remained unchanged in the cytosolic fraction (Fig. 10, chapter 4). 
Suggesting, that 15d-PGJ2 does not involve cellular distribution of mPGES-2 or, most likely it 
could be explained by partial solubilisation of mPGES-2 during homogenisation, because this 
protein was described to be very sensitive to purification conditions (Watanabe K. et al. 
1999). Down-regulation of mPGES-2 by 15d-PGJ2 resulted in a distinct decrease in PGES 
activity in the microsomal fraction in both, Caco-2 and HCT 116 cells, whereas PGES activity 
in the cytosolic fraction remained unchanged. The relatively high level of PGE2 in the 
cytosolic fraction may be explained by a contribution of cPGES to the cytosolic PGE2 
production. The protein concentration of cPGES also remained unchanged following the 
stimulation with 15d-PGJ2 (Fig. 11, chapter 4). 
Differentiated Caco-2 and undifferentiated HCT 116 cells displayed a different 
sensitivity to 15d-PGJ2, which is expressed in a notably discrepancy in mPGES-2 protein 
level and activity reduction between both cell lines. This might be explained by the individual 
features of each cell line, which could represent different stages of carcinogenesis. 
Changes in mPGES-2 mRNA and protein expression levels were not only 
accompanied by a significant reduction in PGES activity but also came along with diminished 
cell proliferation rates. The same antiproliferative effect was exerted by a parent compound, 
cyclopentenone prostaglandin, PGA2. In contrast, exogenously added PGE2 was able to 
completely reverse cyclopentenone prostaglandin action on cell growth. Increased 
proliferation by PGE2 in colorectal cancer cells has already been demonstrated (Sheng H. et 
al. 2001; Mutoh M. et al. 2002). It was shown that PGE2 mediates carcinogenic changes by 
acting on EP1 and EP4 receptors in the colon. EP2 receptor may also be involved in tumour 
progression, triggered by PGE2. In contrast, EP3 does not appear to have influence in early 
stages of colon carcinogenesis (Mutoh M. et al. 2002; Sonoshita M. et al. 2001). Several 
mechanisms responsible for 15d-PGJ2 induced growth inhibition have been described, 
including cell cycle arrest by inhibition of cyclin D1 and stimulation of p21 expression via 
PPARγ-dependent and –independent mechanisms (Miwa Y. et al. 2000; Wang C. et al. 2001; 
Kawakami S. et al. 2002), activation of the mitochondrial apoptosis pathway via inducing 
membranes depolarization and cytochrome c release (Nencioni A. et al. 2003) or by inhibition 
of NF-κB DNA-binding activity (Piva R. et al. 2005). Our findings strongly suggest that 
reduction of PGE2 formation by down-regulation of mPGES-2, at least in part, may also 
contribute to a diminished growth of colon cancer cells in response to 15d-PGJ2. In addition 
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to a current report by Murakami et al. (2003) demonstrating a markedly increased expression 
of mPGES-2 in colorectal cancer tissues, our data further support the hypothesis of an 
involvement of this enzyme in the development of colorectal cancer. Furthermore, the link 
between mPGES-2 and cancer might not be restricted to this tumour entity. Rees et al. (2003) 
showed that two gastric cancer cell lines (MKN-45 and MKN-74) did not express mPGES-1, 
but were still able to synthesize PGE2. Because both, cPGES protein as well as cytosolic 
PGES activity could be detected, the authors assumed the possibility of an interaction of 
COX-2 with cPGES in gastric cancer cells. However, the expression of mPGES-2 was not 
evaluated in these in vitro models of gastric cancer. Moreover, Kino Y. et al (2005) studying 
COX and PGES expression in ovarian cancer have found that mPGES-1 was detected only in 
some cell lines and its presence did not correspond with PGE2 production. Whereas cPGES 
and mPGES-2 were observed in all cell lines, and expression of both enzymes positively 
correlated with elevated PGE2 production. Interestingly, that mPGES-2 and cPGES were 
expressed in concert with COX-1, but not COX-2 and selective COX-2 inhibitors (NS-398 
and rofecoxib) did not inhibit PGE2 production. 
 
5.2 The regulation of mPGES-2 by cyclopentenone prostaglandins is independent 
of nuclear or membrane receptors activation, but may be mediated by covalent binding 
of the cyclopentenone ring to cysteine residues on signalling molecules or via a redox-
dependent mechanism. 
 
In order to find out the responsible mechanism for 15d-PGJ2 induced mPGES-2 
inhibition some of the known mechanisms attributed to the action of this cyclopentenone was 
investigated. 15d-PGJ2 is an activating ligand for PPARγ (Forman B. et al. 1995, Kliewer S. 
et al. 1995) (Fig. 27). Although the affinity of 15d-PGJ2 for PPARγ (EC50 approximately 2 
µM) is significantly lower than that of classical steroid hormones for their cognate 
intracellular receptors, it represents the natural ligand with the highest affinity for PPARγ yet 
identified (Straus D. et al. 2001). 
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Fig. 27. 15d-PGJ2 regulation of PPARγ. After entering the cell by an active transport, 
15d-PGJ2 binds to PPARγ, resulting in PPARγ translocation to the nucleus. 15d-PGJ2 
/PPARγ forms a heterodimer with the nuclear retinoid X receptor (RXR) to recognize PPAR-
response elements (PPRE) in the promoter region of target genes and stimulate transcription. 
 
 
PPARs are members of the nuclear receptor superfamily and include three subtypes, 
PPARα, δ, and γ (Kersten S. et al. 2000). The PPARs form heterodimers with the retinoid X 
receptor and activate gene expression by binding to the peroxisome proliferator response 
element (PPRE) in DNA. PPARγ is the molecular target for thiazolidinedione antidiabetic 
drugs, which bind in a very large ligand binding pocket with the thiazolidinedione ring. The 
cyclopentenone ring of 15d-PGJ2, presumable, occupies the same position as the 
thiazolidinedione ring (Nolte R. et al. 1998). The binding of ligands such as 15d-PGJ2 to 
PPARγ results in activation of transcription of genes that have PPRE located in an enhancer 
or promoter element. 
The role of PPARγ in tumour development remains the subject of intense debate: 
while extensive studies have documented the antiproliferative effects of PPARγ activation, 
equally convincing evidence describes its oncogenic actions using in vivo and in vitro systems 
(Nahle Z. 2004). Studies, using tumour cell lines derived from breast, colon, prostate 
carcinomas and liposarcoma as well as organ cultures have consistently reported growth 
arrest, differentiation or apoptosis upon ligandinduced PPARγ activation (Nahle Z. 2004; 
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Sarraf P. et al. 1998). Moreover, down-regulation of COX-2 expression in colon cancer cells 
via the activation of PPARγ was also demonstrated (Yang W. et al. 2001). There is also some 
evidence, that 15d-PGJ2 may control COX-2 expression through PPARγ-dependent 
mechanism (Inoue H. et al. 2000). In the light of these findings its effect on mPGES-2 in 
Caco-2 PPARγ dominant negative cells was examined. However, regulation of mPGES-2 by 
15d-PGJ2 was not abolished in the absence of active PPARγ. In addition, the synthetic PPARγ 
agonist, MCC555, did not induce any changes in mPGES-2 expression in Caco-2 and HCT 
116 cells, ruling out that down-regulation of mPGES-2 by 15d-PGJ2 is under control of the 
PPARγ pathway. 
There were several reports demonstrating that 15d-PGJ2 can exert its action on cell 
metabolism via binding to cell membrane receptors (Fig. 28). The parent compound, PGD2, 
acts through two such receptors: the DP1 receptor and the DP2 receptor, which is also known 
as the CRTH2 (Powell W. 2003). 15d-PGJ2 activates the DP2 receptor on eosinophils with a 
potency ( [EC50] 10 nM) nearly equal to that of PGD2, the main ligand for this receptor 
(Monneret G. et al. 2002), whereas the EC50 for DP1 is ~320 nM, much higher than that for 
PGD2 (Wright D. et al. 1998). 
 
 
Fig. 28. The effect of 15d-PGJ2 on 
receptors and signalling molecules. Some 
of the effects of 15d-PGJ2 on intracellular 
proteins are mediated through its covalent 
binding to proteins. In addition to its 
effects on intracellular proteins, 15d-PGJ2 
also activates the DP2 and DP1 receptors. 
(Powell W. 2003) 
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DP1 and CRTH2 are seven-transmembrane G protein–coupled
  receptors. DP1 
activation by PGD2 leads to the stimulation of adenylyl cyclase activity and an increase in 
intracellular cAMP levels (Boie Y. et al., 1995). In contrast, activation of CRTH2 by PGD2 
has been shown to lead to an increase in intracellular calcium mobilization in T helper type 2 
cells, eosinophils, and basophiles. (Hirai H. et al., 2001). In order to determine a putative 
involvement of such cellular surface receptors in 15d-PGJ2 mediated regulation of mPGES-2 
expression either signalling pathway of the two receptors was scrutinized in our colorectal 
cancer in vitro models. However, 15d-PGJ2 did not evoke any change in intracellular calcium 
and cAMP did not display any regulatory effect on mPGES-2 protein expression, thereby 
excluding the participation of the PGD2 receptors DP1 and CRTH2 in 15d-PGJ2 induced 
suppression of mPGES-2. PGD2, a potent activator of CRTH2 receptor also did not induce 
any changes in intracellular calcium, suggesting that HCT 116 and Caco-2 colon cancer cells 
most likely do not express CRTH2. 
These findings suggested that control of mPGES-2 by 15d-PGJ2 might not be related 
to a mechanism specific for this cyclopentenone but more likely mediated by mechanisms 
inherent to cyclopentenone prostaglandins in general and may derive from their specific 
chemical properties. The cyclopentenone ring, which determines this eicosanoid family, has 
been suggested to determine the ability of these members to interact with cellular target 
proteins, alkylating exposed cysteine residues (Sanchez-Gomez F. et al. 2004). For example, 
15d-PGJ2 was found to directly inhibit NF-κB-dependent gene expression. In this case, two 
target protein cysteine residues were involved. One of these is located in the IκB kinase, 
which is required for NF-κB activation, and the other is located in the DNA-binding domains 
of NF-κB. This modification led to suppression of COX-2 expression, which is under 
transcriptional control of NF-κB and represent a PPARγ-independent mechanism for negative 
feedback regulation of one of the key enzymes of prostaglandin biosynthesis by 
cyclopentenone prostaglandins (Straus D. et al. 2000, Rossi A. et al. 2000; Tsubouchi Y. et al. 
2001). In contrast to the inhibition of this transcription factor, which plays crucial roles in 
inflammation, immunity, cell proliferation and apoptosis, 15d-PGJ2 could activate H-RAS, 
another well established signalling molecule in colorectal cancer, which may cause a several-
fold increase in mPGES-1 promoter activity (Yoshimatsu K. et al. 2001). This effect was 
mediated by direct interaction of 15d-PGJ2 with Cys-184 of H-Ras, which exists only in the 
H-Ras isoform, whereas N-Ras or K-Ras were not able to bind 15d-PGJ2 ( Oliva J. et al. 
2003). 
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Any member of cyclopentenone prostaglandins family may regulate signalling 
molecules through covalent modification of their cysteine residues. Based on these reports we 
reasoned that other cyclopentenone prostaglandin would display similar biological activities 
on mPGES-2 expression. Indeed, down-regulation of mPGES-2 by 15d-PGJ2 was not unique 
and another cyclopentenone prostaglandin, PGA2, could also mimic these biological actions. 
In contrast, other eicosanoids, which did not possess the cyclopentenone structure, such as 
AA and PGD2 or leukotrienes did not affect mPGES-2 protein expression. These data indicate 
that the cyclopentenone ring structure of 15d-PGJ2 may be involved in the regulation of 
mPGES-2 gene expression. 
Various compounds within the cyclopentenone PG family possess potent anti-
neoplastic activity. The cyclopentenone PGA2 is a potent inhibitor of growth of cultured cells 
and exhibits antitumoural activity in vivo (Lin S. et al. 2000; Marini S. et al. 1990). It was 
noticed that PGE2 may mediate the growth-inhibitory effect in human fibroblasts. Observed 
inhibition of cell growth was postulated to require PGE2 dehydratation to the PGA2. Thus, 
PGA2 was discovered to display antiproliferative properties. (Ohno K. et al. 1986). Indeed, 
PGA2 was also capable to reduce growth of cell lines analysed in this study. Concentrations of 
PGA2 used before to induce cell arrest or apoptosis were in the range of 15-60 µM (Joubert A. 
et al. 2003; Lin S. et al. 2000), whereas in our experiments already 10 µM PGA2 could reduce 
cell proliferation. 
Finally, some of the biological activities specific for cyclopentenone prostaglandins 
was examined. Cyclopentenone prostaglandins were described as inducters of intracellular 
oxidative stress, the most active of which is 15d-PGJ2 (Kondo M. et al. 2001). It was shown 
that this prostaglandin may increase intracellular reactive oxygen species (ROS) production 
(Nencioni A. et al. 2003) and pretreatment with the antioxidant NAC significantly inhibits the 
changes in intracellular redox status caused by cyclopentenones. The fact that cyclopentenone 
PGs are susceptible to nucleophilic addition reactions with thiols suggests that the action of 
cyclopentenone PGs is closely related to a direct reaction with GSH and/or other thiol 
compounds. However, reactive oxygen species (ROS) production was not only the result from 
GSH depletion alone, but also from the reduction of GSH peroxidase activity. GSH 
peroxidase contains a selenocysteine residue, which is essential for peroxidase activity. This 
selenocysteine residue resembles a cysteine residue in terms of chemical properties but with 
higher reactivity. Electrophiles, such as cyclopentenone PGs are likely to react with the 
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selenocysteine residue of GSH peroxidase, resulting in the depletion of GSH peroxidase 
activity (Kondo M. et al. 2001). 
Oxidative stress is increasingly seen as a major upstream component in the signalling 
cascade involved in many cellular functions such as cell proliferation, inflammatory 
responses, stimulating adhesion molecule, and chemoattractant production. Transient 
fluctuations in ROS, generated during oxidative stress, serve important regulatory functions, 
but when present at high and/or sustained levels, ROS can cause severe damage to DNA, 
protein, and lipids. At the cellular level, oxidant injury elicits a wide spectrum of responses 
ranging from proliferation to growth arrest and to cell death. The particular outcome depends 
on the intracellular stress signalling pathways that are activated in response to the oxidative 
insult. These pathways exert their phenotypic influences largely through modulation of 
transcription factor activities that effect changes in the pattern of gene expression (Fig. 29) 
(Martindale J. et al. 2002). 
 
Fig. 29. Oxidative stress activates 
numerous major signalling pathways. 
Being highly reactive by nature, ROS can 
directly or indirectly modulate the 
functions of many enzymes (boxes) and 
transcription factors (ovals) through a 
multitude of signalling cascades as 
depicted here. Ultimately these signals 
result in changes in gene expression, 
which influence the ability of the cell to 
survive or die. The magnitude and 
duration of the stress as well as the cell 
type involved are important factors in 
determining which pathways are 
activated. ATM, ataxia-telangectasia 
mutated kinase; ERK, extracellular 
signal-regulated kinases; HSF1, heat 
shock transcription factor 1; JAK, Janus 
protein kinase; JNK, c-jun N-terminal 
kinases; NFκB, nuclear factor κB; PI3K, 
phosphoinositide 3-kinase; PKC, protein 
kinase C; PLC-γ1, phospholipase C-γ1; 
STAT, signal transducers activators of 
transcription. 
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A number of defence systems have evolved to combat the accumulation of ROS. 
These include various non-enzymatic molecules (e.g., glutathione, vitamins A, C, and E, and 
flavenoids) as well as enzymatic scavengers of ROS (e.g., superoxide dismutases (SOD), 
catalase, and glutathione peroxide). Antioxidants, such as NAC or DTT prevented the effect 
of 15d-PGJ2 caused by induction of oxidative stress. Our data demonstrated that the 
antioxidants NAC and DTT were able to completely abolish the down-regulation of mPGES-
2 protein expression by 15d-PGJ2. However, when in additional experiments oxidative stress 
was induced by ROS directly, mPGES-2 expression was not affected. Since H2O2 may cause 
an oxidative stress and induce ROS production similar to 15d-PGJ2 (Nencioni A. et al. 2003; 
Li L. et al. 2001) we thought that oxidative stress may not be involved in mPGES-2 
expression regulation. Since all these antioxidants possess a thiol group, it is most likely, that 
NAC or DTT bind to 15d-PGJ2, thereby preventing its impact on cellular target proteins. 
Together, these findings provide new insights into the anti-proliferative properties of 
cylopentenone prostaglandins by the inhibition of mPGES-2 in colon carcinoma cells. 
Although the exact mode of action of 15d-PGJ2 on mPGES-2 expression and the role of this 
enzyme in cancerogenesis remains to be determined, we speculate that mPGES-2 might be an 
interesting new target in the prevention of colorectal cancer. However, one important issue 
regarding many of the reported effects of cyclopentenone prostaglandins is whether they can 
be considered of physiological or pharmacological
 significance. Whereas the amount of 15d-
PGJ2 measured in several experimental models are in the nanomolar range (Gilroy D. et al. 
1999), most of the biological effects of 15d-PGJ2 and other cyclopentenone prostaglandins, 
including those described here, have been observed to occur at micromolar concentrations 
(Powell W. 2003). However, our experiments revealed that 1 µM concentration of 15d-PGJ2 
was also able to exert same effect as a 10 µM, but after the longer incubation period. That 
may suggest, nanomolar concentrations of this drug may be also efficient. Thus, in addition to 
defining the physiological role of 15d-PGJ2, additional work is needed to establish the in vivo 
relevant doses of this cyclopentenone for the growth modulating. 
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6. Summary 
 
Clinical, genetic, and biochemical evidence suggests that Prostaglandin (PG) E2 is a 
significant contributor to the development and progression of colorectal cancer (Sheng H. et 
al. 2001; Sheng H. et al. 1998; Ben-Av P. et al. 1995). In addition, increased amount of PGE2, 
has been detected in colorectal adenomas and cancers (Yoshimatsu K. et al. 2001). 
Until now three prostaglandin E synthases in mammals have been identified: cytosolic 
PGES (cPGES), membrane associated PGES (mPGES-1) and membrane-associated PGES 
(mPGES-2) (Tanioka T. et al. 2000; Jakobsson PJ. et al. 1999; Tanikawa N. et al. 2002). 
Among these three known proteins capable to isomerise PGH2 to PGE2, mPGES-1 and 
mPGES-2 were markedly increased in colorectal cancer tissues (Rees B. et al. 2003; 
Murakami M. 2003). While recent data already demonstrated that mPGES-1, in concert with 
Cyclooxygenase-2 (COX-2) (Murakami M. et al. 2000), can be associated with cellular 
transformation and cancer development, until now no such information is available for 
mPGES-2. Thus, there is a particular interest in the identification of a possible role of 
mPGES-2 in the development of colorectal cancer. 
Cyclopentenone prostaglandins are members of prostaglandins family contained a 
cyclopentenone ring structure, which is characterized by the presence of a chemically reactive 
α,β-unsaturated carbonyl. Various members of the cyclopentenone prostaglandin family have 
anti-neoplastic, anti-inflammatory and anti-viral activities (Straus D. et al. 2001). 15-deoxy- 
∆
12,14-prostaglandin J2 (15d-PGJ2), cyclopentenone prostaglandin, was described as a key 
regulator of negative feedback of the COX pathway in an inflammatory setting and as a potent 
anti-tumoral agent (Inoue H. et al. 2000; Tsubouchi Y. et al. 2001; Straus D. et al. 2001). We 
sought to determine its potential implication on PGE2 mediated colorectal cancer promotion. 
The effect of 15d-PGJ2 on gene and protein expression of cytosolic PGES, mPGES-1, 
-2 and COX-1, COX-2 as well as on PGES activity, HCT 116 and differentiated Caco-2 cells 
was investigated. While the expression of mPGES-2 mRNA was down-regulated by 15d-PGJ2 
in both cell lines tested, levels of cPGES, mPGES-1, COX-1 (expressed in HCT 116) and 
COX-2 (expressed in Caco-2) remained unchanged following treatment with this 
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cyclopentenone, indicating that the inhibitory effect of 15d-PGJ2 on mPGES-2 is independent 
of COX-1 or COX-2 expression. 
The down-regulation of mPGES-2 gene expression was followed by a time-delayed 
transient reduction of this enzyme on the protein level. In accordance to the down-regulation 
of this PGES on the mRNA and protein level, a substantial decrease in enzyme activity could 
also be noticed. Together with PGA2, another cyclopentenone, 15d-PGJ2 also displayed a 
growth-inhibitory effect in HCT 116 cells, which was counteracted by PGE2. 
In order to work out the responsible mechanism for 15d-PGJ2 induced mPGES-2 
inhibition we investigated some of the known mechanisms attributed to the action of this 
cyclopentenone. Since 15d-PGJ2 is an established natural ligand of peroxisome proliferator-
activated receptor γ (PPARγ) (Forman B. et al. 1995, Kliewer S. et al. 1995) we examined the 
effect of another PPARγ agonist – the thiazolidinedione homolog MCC 555 on mPGES-2 
mRNA expression. No changes in gene expression of mPGES-2 or any of the other enzymes 
examined (COX-1, COX-2, mPGES-1 and cPGES) after treatment Caco-2 and HCT 116 cell 
lines with this compound were observed. This was further confirmed by subjecting Caco-2 
cells, transfected with a mutant receptor to inhibit wild type PPARγ action, to 15d-PGJ2 
treatment. Gene, protein expression and enzyme activity of mPGES-2 were reduced to a 
similar extent when compared with the non-transfected Caco-2 cell line or HCT 116 cells, 
ruling out that down-regulation of mPGES-2 by 15d-PGJ2 is under control of the PPARγ 
pathway. 
15d-PGJ2 can also exert its action on cell metabolism via binding to the PGD2 
receptors DP1 and Chemoattractant receptor–homologous molecule expressed on TH2 cells 
(CRTH2) (Monneret G. et al. 2002; Powell W. 2003). DP1 activation leads to the stimulation 
of adenylyl cyclase activity followed by an increase in intracellular cAMP levels (Boie Y. et 
al. 1995). CRTH2 activation enhances intracellular calcium mobilization (Hirai H. et al. 
2001). In order to determine a putative involvement of such cellular surface receptors in 15d-
PGJ2 mediated regulation of mPGES-2 expression we therefore investigated whether 
treatment of colon cancers cells with 15d-PGJ2 might induce a calcium release or incubation 
with cAMP would affect mPGES-2 expression. However, 15d-PGJ2 did not evoke any 
changes in intracellular calcium and cAMP display any regulatory effect on mPGES-2 protein 
expression, thereby excluding that 15d-PGJ2 exerts its action by binding to G-protein coupled 
receptors. 
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In addition, 15d-PGJ2 can exert its effect through the mechanisms specific for all 
cyclopentenone, such as oxidative stress induction (Nencioni A. et al. 2003; Kondo M. et al. 
2001). In order to investigate whether oxidative stress is involved in 15d-PGJ2 mPGES-2 
expression inhibitions, Caco-2 and HCT 116 cells were pretreated with or without two 
different antioxidants prior to stimulation with 15d-PGJ2. The 15d-PGJ2 inhibitory effect on 
mPGES-2 protein expression was completely reversed by both antioxidants, Dithiothreitol 
(DTT) and N-acetylcysteine (NAC). However, in additional experiments oxidative stress 
induced by H2O2 did not affect mPGES-2 expression. Thus, it appears likely, that NAC or 
DTT bind to 15d-PGJ2, thereby preventing its impact on cellular target proteins. 
Finally, biological activity of cyclopentenone prostaglandins can derive solely from 
their specific chemical properties. The cyclopentenone ring determines the ability of these 
compounds to interact with cellular target proteins (Straus D. et al. 2001). Therefore we 
treated Caco-2 and HCT 116 cells with PGA2, another cyclopentenone prostaglandin. PGA2 
displayed similar biological actions, whereas eicosanoids not containing the cyclopentenone 
structure, such as PGD2 or leukotrienes did not affect mPGES-2 protein expression. 
Together, our findings provide new insights into the anti-proliferative properties of 
cyclopentenone prostaglandins through the inhibition of mPGES-2 in colon carcinoma cells 
and expose mPGES-2 as a new potential drug target in the treatment of colorectal cancer. 
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7. Zusammenfassung 
 
Das kolorektale Karzinom ist weltweit das dritthäufigste Karzinom. Schon lange 
bekannt ist die antikarzinogene Wirkung von sog. nichtsteroidale Antiphlogistika (NSAIDs), 
(nicht-)selektiven Inhibitoren der Cyclooxygenase-2 (COX-2), in der Entstehung des 
kolorektalen Karzinoms. Eine vergleichbare Wirkung geht von neu entwickelten COX-2-
Inhibitoren aus, die eine selektive COX-2-Hemmung hervorrufen (Brown J. et al. 2005). 
Zahlreiche Untersuchungen von COX-2 nachgeschalteten Prostaglandinen (PG) 
unterstreichen die herausragende Bedeutung von PGE2 in der Ätiopathogenese des 
kolorektalen Karzinoms. So ist die Konzentration von PGE2 in kolorektalen Adenomen und 
Karzinomen regelhaft gesteigert (Yoshimatsu K. et al. 2001). PGE2 führt darüber hinaus in 
vitro zu einer Induktion der Angiogenese in vitro induzieren und Reduktion der Apoptoserate 
(Ben-Av P. et al. 1995). Ferner steigert PGE2 Proliferation und Motilität kolorektaler 
Tumozellen (Sheng H. et al. 1998; Sheng H. et al. 2001). 
Die Biosynthese von PGE2 aus Arachidonsäure (AA) erfolgt über verschiedene 
enzymatische Reaktionen, an denen Phospholipase A2 (PLA2), COX sowie die terminale 
PGE2 Synthasen(PGES) beteiligt sind. Die am besten untersuchte PGES ist ein perinukleäres 
membrangebundenes Enzym, mPGES-1, welche zur MAPEG-Proteinfamilie (MAPEG = 
membrane associated proteins in eicosanoid and glutathione metabolism) gehört (Jakobsson 
PJ. et al. 1999).  Die Expression von mPGES-1 wird durch proinflammatorische Stimuli 
gesteigert und durch Glucocorticosteroide reduziert. Die Expression dieses Enzyms ist dabei 
zumeist an die der COX-2 gekoppelt (Murakami M. et al. 2000). Eine Induktion der 
Expression von mPGES-1 findet sich bei einer Reihe von physiologischen und 
pathophysiologischen Zuständen wie Entzündung, Fieber oder auch der Tumorgenese 
(Murakami M. et al. 2004; Rees B. et al. 2003). Im Gegensatz zu mPGES-1 wird die 
cytosolische Form von PGES (cPGES) in einer Vielzahl von Zelltypen konstitutiv und 
ubiquitär exprimiert. Diese Enzym scheint vorwiegend an die durch COX-1-vermittelte 
PGE2-Bildung gekoppelt zu sein (Tanioka T. et al. 2000). Vor wenigen Jahren wurde ein 
zweites membran-assoziiertes PGES (mPGES-2) identifiziert, das für seine katalytische 
Aktivität im Gegensatz zu mPGES-1 nicht zwangsläufig Glutathion (GSH) als Kofaktor 
benötigt. Auch die mPGES-2 wird 2 in einer Vielzahl von Zellen und Geweben konstitutiv 
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exprimiert. Anders als für mPGES-1 konnte eine Induktion dieses Enzyms im Rahmen 
inflammatorischer Prozesse (Rheumatoide Arthritis, Myokardinfarkt) nicht nachgewiesen 
werden; dagegen werden beide mikrosomale PGES beim humanen kolorektalen Karzinom 
überexprimiert (Tanikawa N. et al. 2002; Murakami M. et al. 2003). 
Cyclopentenon-Prostaglandine sind durch eine Cyclopentenon-Ringstruktur mit 
chemisch reaktionsfähiger α,β-ungesätigten Carbonyl-Gruppe charakterisiert.  Verschiedene 
Vertreter dieser Prostaglandin-Familie weisen antineoplastische, antiinflammatorische und 
antivirale Aktivitäten auf (Ohno K. et al. 1986; Kato T. et al. 1986; Straus D. et al. 2001). 15-
deoxy-∆
12,14-Prostaglandin J2 (15d-PGJ2) ist ein Cyclopentenon-Protaglandin der J-Klasse, 
einem Derivat von PGD2. PGA2, ein Vertreter der A-Klasse, entsteht dagegen durch 
Dehydration von PGE2. Eine Regulation von COX-2 durch 15d-PGJ2 im Rahmen 
inflammatorischer Vorgänge wurde von mehreren Autoren beschrieben. Dieser negative 
Feedback-Mechanismus scheint an der Resolution von Entzündungsprozessen beteiligt zu 
sein und durch eine Hemmung der NF-κB-Aktivität vermittelt zu werden. Darüber hinaus 
hemmt dieser PGD2-Metabolit mPGES-1 in vitro (Quraishi O. et al. 2002).  In der 
vorliegenden Arbeit sollte die mögliche Wirkung von 15d-PGJ2 auf die PGE2-vermittelte 
Entstehung des kolorektalen Karzinoms untersucht werden. 
Die Wirkung von 15d-PGJ2 auf die Gen- und Proteinexpression von cPGES, mPGES-
1 und mPGES-2 sowie COX-1 und COX-2, wie auch die PGES-Aktivität wurde in den 
beiden kolorektalen Tumorzelllinine HCT 116 und Caco-2 untersucht. Dabei zeigte sich eine 
selektive Hemmung der Expression von mPGES-2 durch 15d-PGJ2 an beiden Zelllinine ohne 
Effekt auf andere, an der PGES beteiligten Gene. Die Hemmung der mRNA-Expression von 
mPGES-2 war zeit- und dosisabhängig. Parallel zur Reduktion der mRNA-Expression fand 
sich eine zeitlich verzögerte Abnahme der Proteinkonzentration von mPGES-2. Mehrere 
Studien haben in der Vergangenheit gezeigt, daß die Genexpression von mPGES-1 und COX-
2 einer Ko-Regulation unteliegt (Murakami M. et al. 2000), so dass eine Kopplung der 
Expression von COX-2 mit mPGES-2 durchaus denkbar wäre. Eine verringerte mPGES-2-
Proteinexpression wurde in COX-2
-/--Mäusen beschrieben (Bosetti F. et al. 2004). Andere 
Autoren fanden jedoch keinen Zusammenhang bezüglich der Expression von mPGES-1 und 
COX-2 (Devaux Y. et al. 2001; Masuko-Hongo K. et al. 2004). Darüber hinaus wurde eine 
PGE2-Bildung durch mPGES-2 aus PGH2 mit Hilfe von COX-1 und COX-2 demonstriert 
  69   ZUSAMMENFASSUNG 
(Murakami M. et al. 2003). Dagegen wird für cPGES eine funktionelle Kopplung mit COX-1 
postuliert (Tanioka T. et al. 2000).  
Es gibt Hinweise auf eine Verbindung der der PG-Biosynthese mit 15d-PGJ2 im Sinne 
einer Rückkopplungkontrolle von COX-2 durch diesen PG-Metabolit (Inoue H. et al. 2000; 
Tsubouchi Y. et al. 2001)  Um eine vergleichbare Rückkopplungkontrolle von mPGES-2, 
unter 15d-PGJ2 Behandlung zu untersuchen, wurde die Expression von COX in Zelllinien mit 
verschiedenen Phänotypen bezüglich der beiden COX-Isoformen analysiert: die Caco-2-
Zelllinie exprimiert keine COX-1, während HCT 116-Zellen zur Expression von COX-2 nicht 
in der Lage sind.  Beide Zelllinien wiesen eine vergleichbare Hemmung der Gen- und 
Proteinexpression von mPGES-2 als Folge der 15d-PGJ2-Behandlung auf. Das 
Expressionsniveau von COX-1 und COX-2 beider kolorektaler Tumorzelllinien änderte sich 
nicht, so daß die Hemmwirkung von 15d-PGJ2 auf mPGES-2 keiner Kopplung mit der 
Expression von COX-1 oder COX-2 unteliegt. 
Übereinstimmend mit der transienten Hemmung der Expression von mPGES-2 auf 
mRNA und Proteinebene konnte eine signifikante Abnahme der enzymatischen Aktivität 
beobachtet werden.  Darüber hinaus wiesen sowohl 15d-PGJ2 wie auch PGA2 einen 
wachstumshemmenden Effekt in HCT 116-Zellen auf, der den durch PGE2 hervorgerufenen 
proliferativen Stimulus entgegenwirkt. Neben dieser Wirkung sind für die 15d-PGJ2-
induzierte Wachstumshemmung weitere Mechanismen, wie z.B. Zellzyklusarrest oder 
Aktivierung von mitochondrialen apoptotischen Signalwegen bekannt (Miwa Y. et al. 2000; 
Nencioni A. et al. 2003) Die hier präsentierten Ergebnisse legen nahe, daß die Reduktion der 
PGE2-Bildung über eine Hemmung von mPGES-2 zumindest partiell an dem reduzierten 
Wachstum von HCT 116-Zellen als Antwort auf 15d-PGJ2 beteiligt ist. Zusätzlich zu einer 
kürzlich erschienenen Publikation, bei der eine Überexpression von mPGES-2 in 
kolorektalem Karzinomgewebe nachgewiesen werden konnte (Murakami M. et al. 2003), 
stützen unsere Ergebnisse die Hypothese, daß dieses Enzyms bei der Entwicklung des 
kolorektalem Karzinom beteiligt ist. 
Um den Mechanismus der 15d-PGJ2-induzierten mPGES-2-Hemmung verstehen zu 
können, wurden einige bekannte Reaktionsmechanismen dieses Cyclopentenon untersucht. 
15d-PGJ2 ist ein natürlicher Ligand des Peroxisome Proliferator-Activated Receptor γ 
(PPARγ) (Forman B. et al. 1995, Kliewer S. et al. 1995). Die Bindung von Liganden an 
PPARγ, wie zum Beispiel 15d-PGJ2, führt anschließend zur Aktivierung der Transkription 
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von Genen, die PPAR-response-Elemente (PPRE) in der Enhancer- oder Promotersequenz 
aufweisen. Studien an Tumorzelllinien aus Liposarkomen, Brust-, Kolon- und 
Prostatakarzinomen, aber auch an Organzellkulturen, haben übereinstimmend PPARγ-
vermittelten Wachstumsarrest, Differenzierung und Apoptose gezeigt (Nahle Z. 2004; Sarraf 
P. et al. 1998). Zudem wurde beim Kolonkarzinom auch eine erniedrigte COX-2-Expression 
durch PPARγ-Aktivierung demonstriert (Yang W. et al. 2001). Von einigen Autoren wird 
eine Kontrolle der COX-2-Expression durch PPARγ-abhängige Mechanismen postuliert 
(Inoue H. et al. 2000).  Angesichts dieser Ergebnisse wurde die Wirkung eines weiteren 
PPARγ-Agonisten, des Thiazolidinedionhomologs MCC555, auf die mPGES-2-mRNA-
Expression untersucht. Nach Behandlung von Caco-2- und HCT 116-Zellen mit MCC555 
fand sich jedoch keine Veränderungen in der Genexpression von mPGES-2 wie auch COX-1, 
COX-2, mPGES-1 und cPGES. Dieses Ergebnis wurde durch die Behandlung von Caco-2-
Zellen, bei welchen die PPARγ-Aktivität durch eine dominant negative Rezeptor gehemmt 
wurde, bestätigt. Die Gen- und die Proteinexpression, sowie die enzymatische Aktivität von 
mPGES-2 waren im gleichen Maße reduziert wie in nicht-transfizierten Caco-2-Zellen oder 
HCT 116-Zellen. Eine Kontrolle der Regulation von mPGES-2 durch 15d-PGJ2 über den 
PPARγ-Signaltransduktionsweg kann somit ausgeschlossen werden. 
Als weitere Möglichkeit der Vermittlung 15d-PGJ2–spezifischer Zellefekte ist die 
Bindung an PGD2-Rezeptoren, wie dem DP1 und dem CRTH2 Rezeptor (= Chemoattractant 
receptor–homologous molecule expressed on TH2 cells), beschrieben (Monneret G. et al. 
2002; Powell W. 2003). Die Aktivierung von DP1 führt über eine Stimulierung der 
Adenylcyclase-Aktivität, mit nachfolgender Steigerung der intrazellulären cAMP-
Konzentration (Boie Y. et al. 1995). Die Aktivierung von CRTH2 verstärkt die intrazellulare 
Kalziumfreisetzung (Hirai H. et al. 2001).  Um eine mögliche Einbindung dieser 
Oberflächenrezeptoren an der 15d-PGJ2-vermittelten Regulation der mPGES-2-Expression zu 
überprüfen, wurde eine mögliche Kalziumfreisetzung von Kolonkarzinomzellen nach 
Behandlung mit 15d-PGJ2 untersucht sowie die Expression von mPGES-2 nach cAMP-
Inkubation überprüft.  15d-PGJ2 zeigte jedoch weder Effekte auf die intrazelluläre 
Kalziumkonzentration, noch übte cAMP keine regulatorische Wirkung auf die mPGES-2-
Expression aus. Somit konnte eine Beteiligung dieser Rezeptoren an der Regulation von 
mPGES-2 durch 15d-PGJ2 ausgeschlossen werden. Zusammengefaßt deuten diese Ergebnisse 
darauf hin, daß die 15d-PGJ2-vermittelte Kontrolle von mPGES-2 möglicherweise nicht auf 
einem Mechanismus beruht, der spezifisch für dieses Cyclopentenon-Protaglandin ist, 
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sondern vielmehr auf einem generellen Wirkprinzip von Cyclopentenon-Prostaglandinen 
beruht. So wird ein Teil der biologische Aktivität von Cyclopentenon-Prostaglandinen über 
oxidativen Stress ausgelöst. Dieser basiert auf einer gesteigerten intrazellulären Produktion 
von reaktiven Sauerstoffspezies mit teilweiser Reduktion des GSH-Gehalts. Vorbehandlung 
mit N-Acetylcystein (NAC) verhindert signifikant die Cyclopentenon-Prostaglandin-
abhängigen Veränderungen des intrazellulären Redox-Status (Nencioni A. et al. 2003; Kondo 
M. et al. 2001; Grau R. et al. 2004). Oxidativer Stress kann über einen drastischen Rückgang 
der mitochondrialen Energieproduktion Apoptose induzieren. Außerdem führt die Bildung 
von reaktiven Sauerstoffspezies zur Aktivierung verschiedener Signalmoleküle wie 
beispielsweise NF-κB, p53, Proteinkinase C, MAPK etc., die  zur einer veränderten 
Genexpression führen (Martindale J. et al. 2002).  Um eine potentielle Beteiligung von 
oxidativem Stress an der durch 15d-PGJ2 vermittelten Expressionshemmung von mPGES-2 
zu untersuchen, wurden Caco-2-Zellen und HCT 116-Zellen vor der 15d-PGJ2-Stimulation 
mit verschiedenen Antioxidantien behandelt. Die Hemmwirkung von 15d-PGJ2 auf die 
mPGES-2-Proteinexpression konnte sowohl mit Dithiothreitol (DTT) wie auch NAC 
komplett aufgehoben werden. Dagegen zeigte der durch H2O2 induzierte oxidative Stress 
jedoch keine Auswirkung auf die mPGES-2-Expression. Es ist daher denkbar, daß die 
Antioxidantien NAC oder DTT direkt an 15d-PGJ2 binden und so dessen Wirkung auf 
zelluläre Zielproteine unterbinden. 
Letztlich sind Cyclopentenon-Prostaglandine aufgrund der chemischen Eigenschaften 
ihrer typischen Ringstruktur zur direkten Interaktion mit zellulären Zielproteinen in der Lage. 
So hemmt bsp. 15d-PGJ2 direkt die NF-κB-abhängige Genexpression durch eine kovalente 
Modifikation von Cysteinen in der IκB-Kinase und in den DNA-bindenden Domänen der NF-
κB-Untereinheiten (Straus D. et al. 2000), andererseits wird H-Ras durch eine kovalente 
Modifikation aktiviert (Oliva J. et al. 2003). Cyclopentenon-Prostaglandine modulieren ferner 
die Expression und Aktivität von p53 (Shan Z. et al. 2004), JNK (Liu J. et al. 2003), Egr-1, 
Egr-3, HSP70 (Cippitelli M. et al. 2003) und weiterer, an Zellzyklusregulation und Apoptose 
beteiligter, Transkriptionsfaktoren und Signalmoleküle. In der Tat war die Regulation von 
mPGES-2 nicht auf 15d-PGJ2 begrenzt. Auch PGA2, ein weiteres Cyclopentenon-
Prostaglandin, übte eine der von 15d-PGJ2 vergleichbare biologische Aktivität auf die 
Expression von mPGES-2 in den kolorektalen Tumorzelllinien HCT 116 und Caco-2 aus. 
Andere Eikosanoide, wie PGD2 oder Leukotriene, die über jeweils keine Cyclopentenon-
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Struktur verfügen, oder aber auch Arachidonsäure, Präkursor der Eikosanoide, zeigten keine 
regulatorischen Effekte auf Expression von mPGES-2. 
Mit den hier vorgestellten Resultaten einer Hemmung der Expression von mPGES-2 
und damit auch der PGES-Aktivität in kolorektalen Tumorzelllinien wird das Spektrum der 
antiproliferativen Mechanismen von Cyclopentenon-Prostaglandine erweitert. Die prinzipielle 
Bedeutung dieser Eikosanoide in der Therapie des kolorektalen Karzinoms bleibt jedoch 
offen. Darüber hinaus wurde mit der PGES-2 ein neues interessantes Zielprotein in der 
Theraopie des kolorektalen Karzinoms etabliert, welches sich in der Zukunft als potentiell 
wertvolles Drug-Target erweisen könnte. 
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9. Appendix 
 
Table I 
Sequence of oligonucleotides and PCR conditions 
Gene Primer  sequence  Annealing 
temperature (ºC) 
No. of 
cycles 
G3PDH Forward: 
5’-GCACCGTCAA GGCTGAGAAC-3’ 
Reverse: 
5’-CCACCACCCTGTTGCTGTAG-3’ 
 
45 
 
24 
mPGES-2 Forward: 
5’-CCTGCAGCTGACCCTGTACCAGTA-3’ 
Reverse: 
5’-CCCACTTGTCAGCAGCCTCATAGA-3’ 
51 31 
mPGES-1 Forward: 
5’-GCACGCTGCTGGTCATCAAGATGTA-3’ 
Reverse: 
5’-CCGCTTCCCAGAGGATCTGCAGA-3’ 
49.5 38 
cPGES Forward: 
5’-GCAAAGTGGTACGATCGAAGGGACTAT-3’ 
Reverse: 
5’-CCCAGTCTTTCCAATTATTGAAGTCGA-3’ 
48 33 
COX-2 Forward: 
5’-CCCTTCTGCCTGACACCTTTCAAATT-3’ 
Reverse: 
5’-GCTCTGGATCTGGAACACTGAATGAAGT-3’ 
48 35 
COX-1 Forward: 
5’-GTGGGCTCCCAGGAGTACAGCTAC-3’ 
Reverse: 
5’-GCAATCTGGCGAGAGAAGGCATC-3’ 
48 37 
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